JPH0428699B2 - - Google Patents
Info
- Publication number
- JPH0428699B2 JPH0428699B2 JP57167759A JP16775982A JPH0428699B2 JP H0428699 B2 JPH0428699 B2 JP H0428699B2 JP 57167759 A JP57167759 A JP 57167759A JP 16775982 A JP16775982 A JP 16775982A JP H0428699 B2 JPH0428699 B2 JP H0428699B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- phenyl group
- general formula
- formula
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 229910052757 nitrogen Chemical group 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- -1 alkali metal alkoxide Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000010533 azeotropic distillation Methods 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000005936 piperidyl group Chemical group 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000001414 amino alcohols Chemical class 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 150000003217 pyrazoles Chemical class 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 3
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 3
- 229940039750 aconitine Drugs 0.000 description 3
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 3
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 230000004873 systolic arterial blood pressure Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical compound ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 2
- HDDNBUNZJIQDBQ-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine Chemical compound ClCCCN1CCCCC1 HDDNBUNZJIQDBQ-UHFFFAOYSA-N 0.000 description 2
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 2
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 2
- OXRSFHYBIRFJSF-UHFFFAOYSA-N 3-phenyl-1,4-dihydropyrazol-5-one Chemical compound N1C(=O)CC(C=2C=CC=CC=2)=N1 OXRSFHYBIRFJSF-UHFFFAOYSA-N 0.000 description 2
- CCSRHRVWFHYDAR-UHFFFAOYSA-N 4-[2-[(4-methyl-5-phenyl-1h-pyrazol-3-yl)oxy]ethyl]morpholine Chemical compound N=1NC(C=2C=CC=CC=2)=C(C)C=1OCCN1CCOCC1 CCSRHRVWFHYDAR-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003440 anti-fibrillation Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001008 atrial appendage Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000036279 refractory period Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000723 toxicological property Toxicity 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- WNRWEBKEQARBKV-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine Chemical compound ClCCN1CCCCC1 WNRWEBKEQARBKV-UHFFFAOYSA-N 0.000 description 1
- IJKMZKAORXPIKH-UHFFFAOYSA-N 1-[3-[[5-(4-chlorophenyl)-1h-pyrazol-3-yl]oxy]propyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C1=CC(OCCCN2CCCCC2)=NN1 IJKMZKAORXPIKH-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- NHTDROBHTXFJCI-UHFFFAOYSA-N 3-(4-chlorophenyl)-1,4-dihydropyrazol-5-one Chemical compound C1=CC(Cl)=CC=C1C1=NNC(=O)C1 NHTDROBHTXFJCI-UHFFFAOYSA-N 0.000 description 1
- VBYGLLJSBOALPZ-UHFFFAOYSA-N 3-[[5-(4-chlorophenyl)-1h-pyrazol-3-yl]oxy]-n,n-dimethylpropan-1-amine Chemical compound N1N=C(OCCCN(C)C)C=C1C1=CC=C(Cl)C=C1 VBYGLLJSBOALPZ-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
- ZJGDQYFMDAXNIL-UHFFFAOYSA-N 4-[2-(1h-pyrazol-5-yloxy)ethyl]morpholine Chemical compound C=1C=NNC=1OCCN1CCOCC1 ZJGDQYFMDAXNIL-UHFFFAOYSA-N 0.000 description 1
- ADXFHPJOLYKRJV-UHFFFAOYSA-N 4-[2-[(5-phenyl-1h-pyrazol-3-yl)oxy]ethyl]morpholine Chemical compound C1=C(C=2C=CC=CC=2)NN=C1OCCN1CCOCC1 ADXFHPJOLYKRJV-UHFFFAOYSA-N 0.000 description 1
- OJQPRLGYECDQMW-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-2-piperidin-1-ylpropyl]pyrazol-3-one Chemical compound ClC1=CC=C(C=C1)CC(CC=1C(N=NC=1)=O)N1CCCCC1 OJQPRLGYECDQMW-UHFFFAOYSA-N 0.000 description 1
- WYOLZQSPOVVMKV-UHFFFAOYSA-N 4-methyl-5-phenyl-3-(2-pyrrolidin-1-ylethoxy)-1h-pyrazole Chemical compound N=1NC(C=2C=CC=CC=2)=C(C)C=1OCCN1CCCC1 WYOLZQSPOVVMKV-UHFFFAOYSA-N 0.000 description 1
- XMJKTYVKBFTUSJ-UHFFFAOYSA-N 4-methyl-5-phenyl-3-(pyrrolidin-1-ylmethoxy)-1h-pyrazole Chemical compound N1N=C(C=2C=CC=CC=2)C(C)=C1OCN1CCCC1 XMJKTYVKBFTUSJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- AOWPVIWVMWUSBD-RNFRBKRXSA-N [(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate Chemical compound C[C@@H](O)CCOC(=O)C[C@@H](C)O AOWPVIWVMWUSBD-RNFRBKRXSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DBVADBHSJCWFKI-UHFFFAOYSA-N n-(2-chloroethyl)-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)CCCl DBVADBHSJCWFKI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- USMXXSBPNFTBIA-PHFVEKHWSA-N v6d7xhx354 Chemical compound O[N+]([O-])=O.O([C@H]1[C@]2(O)C[C@H]3[C@@]45[C@H]6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 USMXXSBPNFTBIA-PHFVEKHWSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯æ°èŠãªãã©ãŸãŒã«èªå°äœããããã®è£œ
æ³ããã³ãããã®å»è¬çšéã«é¢ããã æ¬çºæã®ãã©ãŸãŒã«èªå°äœã¯äžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã·ãžã«åºã§ãããR1ãšR2ã¯åäžããŸãã¯ç°
ã€ãŠããŠããããããããæ°ŽçŽ ååãŸãã¯ã¢ã«ã
ã«åºããŸãã¯ããããçµåããçªçŽ ååããã³æŽ
ã«é žçŽ ååãå«æããããšã®ã§ããïŒãïŒå¡ç°ã
圢æããŠããããïœã¯ïŒãïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ãããã³ãã®è£œè¬çã«å容ã§ããå¡©ã§ã
ãã æ¬çºæã¯ãŸãçšæã«å ¥æã§ããå ¬ç¥ã®åæãã
é«åçã§äžè¬åŒïŒïŒã®èªå°äœã補é ã§ããæ¹æ³
ãæäŸããã æ¬çºæã¯ããã«ãŸãã¯å»è¬ç£å»è¬ã«ããããç¹
ã«å¿èäžæŽèã®æ²»çã«å¯Ÿããäžè¬åŒïŒïŒã®ãã©
ãŸãŒã«èªå°äœããã³ãããã®è£œè¬çã«å容ã§ãã
å¡©ã®çšéãæäŸããã äžè¬åŒïŒïŒäžã®Arã§ç€ºãããã¢ãªãŒã«åºã¯
ç¹ã«ïŒãŸãã¯ãã以äžã®ããã²ã³ååã§çœ®æãã
ãŠãããããšãã«åºã§ããåŸããã¯ããã²ã³å
åãŸãã¯çŽéãŸãã¯åæéã®ã¢ã«ãã«åºãäŸãã°
ã¡ãã«ããšãã«ãã€ãœãããã«ãïœâããã«ãïœ
âããã«ãã€ãœã¢ãã«çããŸãã¯ããšãã«ããã
ã¯ãã³ãžã«åºã瀺ãã R1ãšR2ãããããçµåããçªçŽ ååãšå ±ã«è€
çŽ ç°ã圢æãããšãã¯ããã®è€çŽ ç°ã¯ççŽ ååã«
ãã€ãŠå®å šã«ãããåºãäŸãã°ãããªãžãã«ãã
ããªãžã«åºçã§ããåŸãããã®è€çŽ ç°ã¯ãŸãïŒãŸ
ãã¯ãã以äžã®ç°ååãäŸãã°çªçŽ ããã³é žçŽ ã
å«æããããšãã§ããäŸãã°ãªããµãŸãªãžãã«ã
ããã©ãžãã«ãã¢ã«ããªãã«åºçã代衚çã§ã
ãã äžã®äžè¬åŒïŒïŒã«ãããŠãArã¯å¥œãŸããã¯
ããšãã«åºããããã¯ïŒãŸãã¯ãã以äžã®ããã²
ã³ååãäŸãã°å¡©çŽ ãèçŽ ãŸãã¯ããçŽ ã§çœ®æã
ããããšãã«åºãäŸãã°ïœâã¯ããããšãã«åºãŸ
ãã¯ïŒïŒïŒâãžã¯ããããšãã«åºã瀺ããã¯å¥œ
ãŸããã¯ããã²ã³ååãççŽ æ°ïŒãïŒã®äœçŽã¢ã«
ãã«åºãäŸãã°ã¡ãã«ããšãã«ãŸãã¯ãããã«
åºããããã¯ãã³ãžã«åºã瀺ããR1ãšR2ã¯å¥œãŸ
ããã¯ççŽ æ°ïŒãïŒã®äœçŽã¢ã«ãã«åºãäŸãã°ã¡
ãã«ãŸãã¯ã€ãœãããã«åºã瀺ããR1ãæ°ŽçŽ å
åã§ãããšãã¯R5ã¯ã¢ã«ãã«åºã§ããããŸãã¯
ãããšåå¿ã§ããããããã¯äžèšã®è€çŽ ç°ãç¹ã«
ãããªãžãã«ããããªãžã«ããªããµãŸãªã³ãžã
ã«ãããã©ãžãã«ãŸãã¯ã¢ã«ããªãã«åºãäžç·ã«
圢æãããïœã¯å¥œãŸããã¯ïŒãŸãã¯ïŒã§ããã æ¬çºæã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã«ã¯äžåŒïŒïŒããã³äžã®åŒïŒïŒ¡ïŒãšåŒ
ïŒïŒ¢ïŒã§ç€ºãããããã€ãã®åœ¢ãååšããã ïŒïŒããã³ïŒïŒ¡ïŒã®åœ¢ãæ¯é çã§ã¯ãã
ãããããå€éšçãªèŠå ã«ãã平衡ãïŒïŒ¢ïŒåœ¢
ã®æ¹ã«å€ããããšãããåŸããæ¬çºæã¯ãã¡ãã
äžã«ç€ºããïŒïŒãïŒïŒ¡ïŒããã³ïŒïŒ¢ïŒåœ¢ã®ã
ã¹ãŠã«ãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âã
ã©ãŸãŒã«ã«é¢ãããã®ã§ããã æ¬çºæã¯ãŸãäžã®äžè¬åŒïŒïŒã«ãã瀺ããã
ãã©ãŸãŒã«èªå°äœã®å¡©ãç¹ã«éåžžã®é±é žãŸãã¯æ
æ©é žãäŸãã°å¡©é žãç¡«é žãä¹³é žãã·ãŠãŠé žãã¯ãš
ã³é žããªã³é žãã¹ãã¢ãªã³é žããã¬ã€ã³é žãé ç³
é žçã該èªå°äœãšåå¿ãããããšã«ãã€ãŠåŸãã
ã補è¬çã«å容ã§ããå¡©ãæäŸãããã®ã§ããã
åå¿ã¯é žãšè©²èªå°äœãšãå®è³ªçã«ååŠéè«å²åã§
äžè¬ã«åå¿ãããéåžžã®æè¡ãçšããŠè¡ãªãããš
ãã§ããã æ¬çºæã«ããäžè¬åŒïŒïŒã§ç€ºããããã©ãŸãŒ
ã«èªå°äœã¯åŒïŒïŒ ïŒåŒäžãArãšïŒ²ã¯åŒïŒïŒã®å Žåãšåãæå³
ãæã€ïŒ ã®ãã©ãŸãã³ãããoå¡©åºæ§åªäœäžã§äžè¬åŒ
ïŒïŒ âïŒCH2ïŒoâNR1R2 ïŒïŒ ïŒåŒäžãã¯å¡©çŽ ãŸãã¯èçŽ ã®ãããªããã²ã³å
åã瀺ããïœïŒR1ããã³R2ã¯äžè¬åŒïŒïŒäžã§
å®çŸ©ãããšããã®ãã®ã§ããïŒ ã®ããã¢ã«ãã«ã¢ãã³ã§ã¢ã«ãã«åããããšã«ã
ã€ãŠè£œé ããããšãã§ããã åºçºç©è³ªãšããŠçšããããåŒïŒïŒã®ïŒâã¢ãª
ãŒã«âãã©ãŸãã³ã¯å ¬ç¥ã®ååç©ã§ãããæ £çšæ
è¡ãäŸãã°ãã¶ã»ã±ãã¹ããªãŒã»ãªãã»ããããµ
ã€ã¯ãªãã¯ã»ã³ã³ããŠã³ãºãWeissbergerïŒEd.ïŒ
Intersciences Publ.ïŒïŒ1964ïŒäžã«èšèŒãããæ¹
æ³ã«åŸã€ãŠäœãããšãã§ããã åŒïŒïŒã®ïŒâã¢ãªãŒã«ãã©ãŸãã³ãšåŒïŒïŒ
ã®ããã¢ã«ãã«ã¢ãã³ãšã®ã¢ã«ãã«ååå¿ã¯å¡©åº
æ§åªäœäžã§å¡©åºãäŸãã°æ°ŽçŽ åç©ãã¢ãããçé ž
å¡©ãŸãã¯ã¢ã«ã«ãªéå±ã¢ã«ã³ãã·ããŸãã¯ã¢ãã³
ã®ååšäžã§ãé©åœãªææ©æº¶åªäžã§è¡ãªãããšãã§
ããã ãã®åå¿ã¯äŸãã°æ°ŽçŽ åãããªãŠã ããããªãŠ
ã ã¢ãããæ°ŽçŽ åã«ãªãŠã ããããªãŠã ãšãã¬ãŒ
ããçé žã«ãªãŠã ãçé žãããªãŠã ããžãšãã«ã¢
ãã³ãããªãšãã«ã¢ãã³çã®ååšäžã§ããžã¡ãã«
ãã«ã ã¢ããããžã¡ãã«ã¹ã«ããã·ãããžãªããµ
ã³ãããã©ããããã©ã³ãã¡ã¿ããŒã«ãŸãã¯ãšã¿
ããŒã«ã®ãããªã¢ã«ã³ãŒã«ãããã³ã¢ã»ãã³ã®å
ããéžãã 溶åªäžã§è¡ãªãããšãã§ããã溶åªã
ã¢ã«ã³ãŒã«ã®ãšãã¯ãå¡©åºãšããŠã¯çžåœããã¢ã«
ã³ãã·ããäŸãã°ãšã¿ããŒã«äžã®ãããªãŠã ãšã
ãã·ããçšããããšã奜ãŸãããæ¬çºæã«ãã
ã°ã奜ãŸããã¯ãžã¡ãã«ãã«ã ã¢ããäžã®æ°ŽçŽ å
ãããªãŠã ããžãªããµã³äžã®çé žå¡©ãŸãã¯ãšã¿ã
ãŒã«äžã®ãããªãŠã ãšããã·ããçšããããã åå¿ã¯åšå²æž©åºŠã§èµ·ããããåå¿ãä¿é²ããã
ãã«åå¿æ··åç©ã30ã100âã奜ãŸããã¯40ã70
âã®æž©åºŠã«å ç±ããããšã奜ãŸããã æ¬çºæã®è£œæ³ã«ããã奜ãŸããæ¹æ³ã«ããã°ã
åŒïŒïŒã®ãã©ãŸãã³ã¯çªçŽ é°å²æ°äžã§ææ©æº¶æš¹
ã«æº¶è§£ãããå¡©åºãäŸãã°æ°ŽçŽ åãããªãŠã ãç
é žã«ãªãŠã ãŸãã¯ãããªãŠã ã¢ãããæ·»å ããã
æ··åç©ã¯æ¬¡ãã§å°ãå ç±ããããããŠåŒïŒïŒã®
ããã¢ã«ãã«ã¢ãã³ãé£ç¶çã«æ·»å ãããã溶åª
ã¯æžå§äžã§èžçºã«ããé€å»ãããåŸãããçæç©
ã¯éåžžã®ã¢ã·ãâå¡©åºãŸãã¯ã¯ãããã°ã©ãæœåº
æè¡ãçšããŠç²Ÿè£œãããã æ¬çºæã®æ¹æ³ã«åŸã€ãŠåŒïŒïŒã®ãã©ãŸãã³ã®
ã¢ã«ãã«åãè¡ãªãããã«çšããåŒïŒïŒã®ãã
ã¢ã«ãã«ã¢ãã³ã¯äžè¬ã«ã¯ãããã®å¡©é žå¡©ã®åœ¢ã§
åæ¥çã«å ¥æããããšãã§ããã䜿çšãããšã
ã¯ããããã®å¡©é žå¡©ãçžåœããå¡©åºã«å€ããããš
ã奜ãŸããããããã¯Fieser ïŒ FieserïŒ
Reagents for Organic SynthesisïŒNo.ïŒ
John Wiley ïŒ SonsïŒ1974ïŒã«èšèŒãããæ¹
æ³ã«åŸã€ãŠãããã®å¡©é žå¡©ãçé žã«ãªãŠã ã§é£œå
ãã溶液ã«æº¶ããã次ãã§æœåºããããšã«ãã€ãŠ
è¡ãªãã âïŒïŒâã¯ãããšãã«ïŒâãžã¡ãã«ã¢ãã³ã
âïŒïŒâã¯ãããããã«ïŒâãžã¡ãã«ã¢ãã³ãŸãã¯
âïŒïŒâã¯ãããšãã«ïŒâãžã€ãœãããã«ã¢ã
ã³ããŸãã¯è€çŽ ç°åŒããã¢ã«ãã«ã¢ãã³ãäŸãã°
âïŒïŒâã¯ãããšãã«ïŒâãããªãžã³ãâïŒïŒ
âã¯ãããšãã«ïŒâãããªãžã³ãâïŒïŒâã¯ãã
ãããã«ïŒâã¢ã«ããªã³ãâïŒïŒâã¯ããããã
ã«ïŒâãããªãžã³çã§ããæ¬çºæã«ãã䜿çšãã
åŸãæçšãªããã¢ã«ãã«ã¢ãã³ã®äŸãšããŠç¹ã«å
æããããšãã§ããã æ¬çºæã®ä»ã®è£œæ³ã«ããã°ãäžè¬åŒïŒïŒã®ã
ã©ãŸãŒã«èªå°äœã¯äžè¬åŒïŒïŒ ïŒåŒäžãArãšïŒ²ã¯åŒïŒïŒã®å Žåãšåãæå³
ããã€ïŒ ã§ç€ºããããšãã«ã¢ãã€ã«ã¢ã»ããŒãããäœã
ããšãã§ããããã¯åŒïŒïŒ HOâïŒCH2ïŒoâNR1R2 ïŒïŒ ïŒåŒäžãïœïŒR1ããã³R2ã¯åŒïŒïŒã®å Žåãš
åãæå³ããã€ïŒ ã§ç€ºãããã¢ããã¢ã«ã³ãŒã«ãçšãããšã¹ãã«
亀æåå¿ã«ãã€ãŠå€æããããšã«ããåŒïŒïŒ ã®ååç©ãåŸãé žåªäœäžã®ããã©ãžã³ãçšããŠç°
åãè¡ãªããäžè¬åŒïŒïŒã®èªå°äœãçæãã
ãã åŒïŒïŒã®ãšãã«ã¢ãã€ã«ã¢ã»ããŒãã®åŒ
ïŒïŒã®ã±ãã³ãšã¹ãã«ãžã®äº€æãå¯èœã«ãããš
ã¹ãã«äº€æåå¿ã¯å¥œãŸããã¯å ±æ²žèžçãå¯èœã«ã
ã溶åªäžã§å ç±ããããšã«ãã€ãŠè¡ãªããããã
ãã«ãé žè§Šåªã®ååšäžã«åå¿ãè¡ãªãããšã奜ãŸ
ããã溶åªã¯äŸãã°ãã«ãšã³ãŸãã¯ãã·ã¬ã³ã®ã
ããªçåæ°ŽçŽ ã§ããåŸãã é žåªäœãäŸãã°æ¿å¡©é žãŸãã¯ç¡«é žåªäœäžã®ãã
ã©ãžã³ãçšããç°ååå¿ã¯H.J.Backer ïŒ W.
MeierïŒRec.Trav.Chim.P.B.ïŒ45ïŒ428ïŒ1926ïŒ
ã®æ¹æ³ãšé¡äŒŒããæ¹æ³ã«åŸã€ãŠè¡ãªãããšãã§ã
ãã 次ã®äŸã¯ãã®ç¯å²ãéå®ããããšãªãæ¬çºæã
äŸç€ºãããã®ã§ããã äŸ ïŒ ïŒâïœâã¯ããããšãã«âïŒâãžã¡ãã«ã¢ããã
ãããã·âãã©ãŸãŒã«ã®è£œé ãžãªããµã³70mläžã®ïŒâïœâã¯ããããšãã«â
ãã©ãŸãã³9.5ïœãæªææ©ã枩床èšãåçž®åšãæµ
管ããã³çªçŽ å ¥å£ãåãã500ml容ãã©ã¹ã³äžã«
å ¥ãããçªçŽ é°å²æ°äžã§ããããéæµãã次ãã§
çé žã«ãªãŠã ïŒïœãå ãããéæµäžã§ïŒæéå ç±
ããåŸãåå¿åªäœãéæµãã€ã¥ããªããïŒâãžã¡
ãã«ã¢ããâïŒâã¯ãããããã³7.2ïœãå ããã
æ·»å ã¯45åéé£ç¶çã«è¡ãªããããæ··åç©ãçŽïŒ
æééæµãã€ã¥ãã次ãã§ã¢ã·ãâå¡©åºæœåºãæ £
çšæè¡ãçšããŠæžå§èžçºã«ãã溶åªã®é€å»åŸã«è¡
ãªã€ãã ãããµã³ã次ãã§ã€ãœãããã«ãšãŒãã«äžã§å
çµæ¶ããåŸãïŒâïœâã¯ããããšãã«âïŒâãžã¡
ãã«ã¢ããããããã·âãã©ãŸãŒã«6.6ïœãåŸã
ïŒåç47ïŒ ïŒã èç¹ 114âïŒã€ãœãããã«ãšãŒãã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒÎœïŒ3130ïŒ3100ïŒ 1510ïŒ1490cm-1ã NMRã¹ãã¯ãã«ïŒCDCl3ïŒÎŽïŒ1.7ã2.7ïŒ4HïŒïŒ 2.2ïŒïœïŒ6HïŒïŒ4.0ïŒïœïŒ2HïŒïŒ 5.8ïŒïœïŒ1HïŒïŒ7.3ïŒïœïŒ4HïŒïŒ 11.2ïŒïŒ³ïŒ1HïŒppm äžèšååç©ã®ãã¬ã€ã³é žå¡©ã¯æ £çšæè¡ã«åŸã€ãŠ
ãšã¿ããŒã«äžã§ãã¬ã€ã³é žãšåå¿ãããããšã«ã
ã€ãŠè£œé ããã èç¹ 155â äŸ ïŒ ïŒâããšãã«âïŒâã¡ãã«âïŒâãããªãžããšã
ãã·âãã©ãŸãŒã«ã®è£œé äŸïŒãšåæ§ã«ãïŒâããšãã«âïŒâãã©ãŸãã³
ïŒïœããžãªããµã³60mlã«æº¶ãããçªçŽ é°å²æ°äžã§
éæµããªããå ç±ãã次ãã§çé žã«ãªãŠã 3.9ïœ
ãå ãããåå¿æ··åç©ãéæµããªããçŽïŒæéä¿
ã¡ã次ãã§ïŒ®âïŒïŒâã¯ãããšãã«ïŒãããªãžã³
13ïœãé£ç¶çã«å ããã åå¿åŸïŒæéãæ··åç©ãéæµããªããä¿ã¡ã次
ãã§æº¶åªãæžå§èžçºã«ããé€å»ããããã«æœåºã
è¡ãªã€ãã ã·ã¯ããããµã³äžã§åçµæ¶ããåŸãïŒâããšã
ã«âïŒâã¡ãã«âïŒâãããªãžãã¡ããã·âãã©
ãŸãŒã«3.5ïœãåŸãïŒåç26ïŒ ïŒã èç¹ïŒ88âïŒã·ã¯ããããµã³ïŒ èå±€ã¯ãããã°ã©ãã€âïŒTLCïŒïŒ RïŒ0.4ïŒé ¢é žãšãã«ïŒ10ïŒ ãžãšãã«ã¢ãã³ïŒ æ £çšæè¡ã«ããåŸãçžåœãããã¬ã€ã³é žå¡©ã¯è
ç¹158ã159âïŒãšã¿ããŒã«ïŒãæããŠããã äŸ ïŒ ïŒâã¯ããããšãã«âïŒâãããªãžãããããã·
âãã©ãŸãŒã«ã®è£œé ïŒâïœâã¯ããããšãã«âãã©ãŸãã³19.4ïœã
ãã³ç¡æ°Žãžã¡ãã«ãã«ã ã¢ãã60mlãå¡©åã«ã«ã·
ãŠã 管ãæããåçž®åšãæµç®¡ã枩床èšããã³çªçŽ
å ¥å£ãåãã500ml容ãã©ã¹ã³ã«å ¥ããã次ãã§
溶液äžã«çªçŽ ã泡ç«ãŠãªããéãããšã«ãã溶液
ãè±æ°ãããæ··åç©ãçŽïŒâã«å·åŽããã€ãã§æ°Ž
çŽ åãããªãŠã 2.8ïœãå ãããæ··åç©ã®æž©åºŠã
åšå²æž©åºŠã«ãã©ããã€ãã§40âã«é£ç¶çã«å ç±ã
ããïŒâã¯ãããããã«âãããªãžã³17.4ïœã滎
å ããçŽ10æéåå¿ãããã 溶åªãæžå§èžçºãããåŸãã¢ã·ãâå¡©åºæœåºã
ããã³ã€ãœãããããŒã«äžã§ã®åçµæ¶ãè¡ãªãã
ãšã«ããïŒâïœâã¯ããããšãã«âïŒâãããªãž
ãããããã·âãã©ãŸãŒã«10.7ïœãåŸãïŒåç30
ïŒ ïŒãããã«ã粟補äžã«åæïŒâïœâã¯ããããš
ãã«âïŒâãã©ãŸãã³ã®çŽ25ïŒ ããã³ïŒæ¬¡çæç©
ãšããŠïŒâïœâã¯ããããšãã«âïŒâãããªãžã
ãããã«âãã©ãŸãã³çŽïŒïœãååããã èç¹ïŒ140âïŒã€ãœãããããŒã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒïŒÎœïŒ3250ïŒ1510cm
âïŒ NMRã¹ãã¯ãã«ïŒCDCl3ïŒïŒÎŽïŒ1.6ïŒ6HïŒïŒ2.1
ïŒ2HïŒïŒ 2.6ïŒ6HïŒïŒ4.3ïŒïœïŒ2HïŒïŒ 6.2ïŒïœïŒ1HïŒïŒ7.8ïŒïœïŒ4HïŒppm äŸ ïŒ ïŒâããšãã«âïŒâã¡ãã«âïŒâã¢ã«ããªããšã
ãã·âãã©ãŸãŒã«ã®è£œé äŸïŒã®æ¹æ³ãçšããŠãïŒâããšãã«âïŒâãã©
ãŸãã³ïŒïœããžãªããµã³60mlã«æº¶ããããããã
éæµããªããå ç±ããçé žã«ãªãŠã 4.1ïœãå ãã
ã€ãã§é£ç¶çã«ïŒ®âïŒïŒâã¯ãããšãã«ïŒã¢ã«ã
ãªã³7.8ïœãå ããã åå¿ãçµäºãããšããæœåºããã³ã€ãœãããã
ãŒã«äžã§ã®åçµæ¶ãè¡ãªããïŒâããšãã«âïŒâ
ã¡ãã«âïŒâã¢ã«ããªããšããã·ãã©ãŸãŒã«5.1
ïœãåŸãïŒåç36ïŒ ïŒã èç¹ïŒ100âïŒã€ãœãããããŒã«ïŒ TLCïŒRïŒ0.60ïŒé ¢é žãšãã«ïŒ10ïŒ ãžãšãã«ã¢
ãã³ïŒ æ £çšæè¡ã«ãããšã¿ããŒã«äžã§ãã¬ã€ã³é žãšå
å¿ãããããšã«ãã€ãŠäœã€ãçžåœãããã¬ã€ã³é ž
å¡©ã¯èç¹156âãæããŠããã äŸ ïŒ ïŒâããšãã«âïŒâã¢ã«ããªããšãã·ãâãã©ãŸ
ãŒã«ã®è£œé å ±æ²žèžçè£ çœ®ãšæµç®¡ãåãã250ml容ãã©ã¹ã³
äžã§ãã³ãŸã€ã«é ¢é žãšãã«9.6ïœããã³ïŒ®âïŒïŒâ
ããããã·ãšãã«ïŒã¢ã«ããªã³19.7ïœããã«ãšã³
100mlã«æº¶ãããã ããã沞ç¹ãŸã§å ç±ãããã«ãšã³âãšã¿ããŒã«
å ±æ²žæ··åç©ãèžçããåæã«çŽç²ãªãã«ãšã³ãå
ãããåå¿ã¯äºå®äžçŽïŒæéåŸã«å®å šã«çµäºã
ãããã«ãšã³ãèžçæ°Žã§æŽããã€ãã§å¡©åã«ã«ã·
ãŠã 飜åæ°Žã§æŽã€ãåŸãç¡«é žãããªãŠã äžã§ä¹Ÿç¥
ãã也ç¥ãããŸã§èžçºãããããã®ããã«ããŠã¢
ã«ããªããšãã«ãã³ãŸã€ã«ã¢ã»ããŒã12.4ïœãé»
è²ãæ²¹ã®åœ¢ã§åŸãïŒåç90ïŒ ïŒã æ°Žåããã©ãžã³0.3ïœç¡æ°Žãšã¿ããŒã«15mlãã
ã³æ¿å¡©é ž1.6mlã100ml容ãã©ã¹ã³ã«å ¥ããããã
ãéæµæž©åºŠã«å ç±ããäžèšã®ã¢ã«ããªããšãã«ã
ã³ãŸã€ã«ã¢ã»ããŒã1.4ïœãå ãããæ··åç©ãé
æµããªããçŽïŒæéä¿ã¡ãåå¿ãäºå®äžå®å šã«çµ
äºãããããšã¿ããŒã«ãæžå§èžçãããã€ãã§å
å¿çæç©ãæ°Žã§æŽããã¯ãããã«ã ã§æœåºããïŒ
âãšããã³âïŒâããšãã«âãã©ãŸãŒã«çŽ0.1ïœ
ãåé¢ãããæ°Žæ§çžãã¢ã«ã«ãªæ§ã«ããã€ãã§ã¯
ãããã«ã ã§æœåºããããšã«ããïŒâããšãã«â
ïŒâã¢ã«ããªããšããã·âãã©ãŸãŒã«0.5ïœãåŸ
ãïŒåç36ïŒ ïŒã èç¹ïŒ100âïŒã€ãœãããããŒã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒÎœïŒ3260ïŒ1595ïŒ 1510cm-1ã äŸ ïŒã23 äŸïŒã®æ¹æ³ãçšããŠããã ãåæãã©ãŸãã³ã
ãã³ããã¢ã«ãã«ã¢ãã³ãé©åœã«å€æŽããŠäžè¡šã«
瀺ããçæç©ããã³ãããã®å¡©ãåŸãããããã®
ç¹æ§ïŒèç¹ãåçµæ¶æº¶åªããã³10ïŒ ãžãšãã«ã¢ã
ã³ãå ããé ¢é žãšãã«ããæã溶é¢å€ã«ããèè
ã¯ãããã°ã©ãã€ãŒïŒããŸãåè¡šã«ç€ºãããŠã
ãã ãè¡šã ãè¡šã ãè¡šã æ¬çºæã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã«ã€ããŠè¡ãªã€ãè©äŸ¡ã¯è©²ååç©ãç£å»è¬
ããã³å»è¬ã«ãããŠæçšãªãã®ãšããèå³æ·±ãè¬
çåŠçãã€æ¯ç©åŠçç¹æ§ã瀺ããã æ¯ç©åŠçç¹æ§ æ¬çºæã®èªå°äœã®æ¥æ§æ¯æ§ã¯ããŠã¹ïŒ10å¹ãçš
éåœãéïŒå¹ããã³éïŒå¹ïŒã«å¯Ÿããçµå£æäž
ïŒP.O.ïŒäžŠã³ã«Litchfieldããã³WilcoxonïŒJ.
Pharmacol.ïŒ96ïŒ99â113ïŒ1949ïŒïŒã®æ¹æ³ã«åŸã€
ãèŽæ»çšé50ïŒLD50ïŒã®ç®å®ã«ãã調ã¹ããè¡šïŒ
ã¯æ¬çºæã®èªå°äœã®LD50å€ã瀺ããŠããã ããã€ããã®äºäŸã§ã¯ãLD50ã¯ãŸã該èªå°äœ
ã®è ¹è å 泚å°ïŒI.P.ïŒåŸã«èª¿ã¹ãããã åŸãããçµæãäžã«ç€ºãã ãè¡šã ãè¡šã è¬çåŠçç¹æ§ ïŒ å¿èè¡ç®¡ã®èæ§ å¿èè¡ç®¡ã®èæ§ã¯ãåé¢ããã¢ã«ã¢ããã®å¿
è³ã麻é ããã©ããããã³åãã麻é ããç¬ã«ã€
ããŠèª¿ã¹ãã ã¢ã«ã¢ããã®å¿è³ã«ã€ããŠã¯ã該詊æã¯ã¢ã«ã¢
ããã®å¿è³ã®å¿çå±€ã®åçž®å䞊ã³ã«å¿è³ã®åçž®ã®
é »åºŠã®æž¬å®ãå¯èœã«ããã济液ã®10ÎŒïœïŒmlã®æ¿
床ã§ã¯ãè©Šéšãããèªå°äœã¯äºååŠçå¯Ÿç §æéã«
é¢ããŠ15ã75ïŒ ã®åçž®é »åºŠã®æžå°ïŒå¹³åâ43.25
ïŒ ïŒãããããããåãæ¿åºŠã§ãåçž®åã¯å¯Ÿç §æ
éã«é¢ããŠïŒãâ80ïŒ å€åããïŒå¹³åå€åçâ
37.5ïŒ ïŒã 麻é ããã©ããã«ã€ããŠã¯ãïŒã25ïœïŒKgã®çš
éã§æäžãããæ¬çºæã®èªå°äœã¯å¿ææ°
ïŒcardiac frequencyïŒã®æžå°ïŒïŒã40ïŒ ïŒã倧å
èã®æµéã®æžå°ãããã³åçž®æã®åèå§ã®æžå°
ïŒïŒã60ïŒ ïŒããããããã 麻é ããç¬ã«ã€ããŠã¯ãè¡æµååŠçèæ§ã«é¢ã
ãŠåŸãçµæãäžã®è¡šã«èŠçŽãããè¡šïŒã¯äŸïŒãã
ã³ïŒã®èªå°äœã«å¯ŸããäºååŠçå¯Ÿç §æéã«é¢ãã
è¡æµååŠçãã©ã¡ãŒã¿ãŒã®å€åçïŒïŒ ïŒã瀺ãã
ã®ã§ããã ãããã®ãã©ã¡ãŒã¿ãŒã¯æ¬¡ã®æ段ã«ããèšé²ã
ããã â å§åã»ã³ãµãŒã«çµåããã«ããŒãã«ïŒåè
å§ãå·Šå¿å®€ã®å§åããã³ãã®ç¬¬ïŒèªå°äœdpïŒ
dtïŒ â 倧åèäžã®é»ç£æµéèšïŒå€§åèã®æµéïŒ â å¿é»èš â å·Šå¿å®€ã®å¿çå±€äžã«èšçœ®ããã¹ãã¬ã€ã³ã²
ãŒãžïŒã²ãã¿èšïŒïŒå¿çå±€ã®åçž®åïŒ è©²èªå°äœãçŽ30åæ¯ã«ïŒçšéã¥ã€éèå ã«æ³šå°
ãããããŠãããã®å¹æã泚å°çµäºåŸ ïŒæ³šå°ã®
æèŠæéã¯ïŒåïŒ20åçµéããŠãã枬å®ããã ãè¡šã åçž®å
(dpïŒdt) ïŒ âïŒ â30 â30 â38 â46
ïŒp
泚ïŒå¹æã¯äºååŠçå¯Ÿç §æéã«é¢ããå€
åç(ïŒ )ãšããŠè¡šããã
è¡šïŒã«ç€ºããçµæãããã³æ¬çºæã®ä»ã®èªå°äœ
ã«ã€ããŠåŸãããé¡äŒŒã®çµæã¯ãç¬ã«å¯ŸããŠæ¬¡ã®
ãããªè»œæžïŒç·©åïŒãããç¶æ ãããããããšã
瀺ããŠããã â åçž®æã®åèå§ã¯å€åããªãïŒäŸïŒããã³ïŒ
ã®èªå°äœïŒãããŸãã¯é©åºŠã«äœäžããïŒäŸïŒã
14ããã³19ã®èªå°äœïŒãããããäŸNo.ïŒã®èªå°
äœã«å¯ŸããŠã¯ãã®æžå°ã¯4.5mgïŒKgã®èç©çšé
åŸã«çŸãããã«ãããªãã â å¿ææ°ã¯å€åããªãïŒäŸïŒããã³19ã®èªå°
äœïŒãããŸãã¯é©åºŠã«æžå°ããïŒäŸïŒãïŒãã
ã³14ã®èªå°äœïŒã â å¿èã®æµéã¯ãã¹ãŠã®å Žåã«äœäžããããã
ããªãããïŒmgïŒKgããå€ãèç©çšéïŒäŸïŒã
ïŒããã³19ã®èªå°äœïŒãŸãã¯ïŒïœïŒKgããå€ã
èç©å®¹éïŒäŸïŒã®èªå°äœïŒã«ãã€ãŠãã20ïŒ ã®
æžå°ã«éããçšåºŠã§ããããããã®ãããªå€å
ïŒäœäžïŒã¯äŸç¶ãšããŠé©åºŠãªãŸãŸã§ããã â å¿å®€ã®å¿çå±€ã®åçž®åã¯ãäŸNo.ïŒã®èªå°äœã®
泚å°åŸã«ã¯å¢å ããäŸNo.ïŒããã³14ã®èªå°äœã«
ã€ããŠã¯é¡èã«å€åããããšã¯ãªããäŸNo.ïŒã
ãã³19ã®èªå°äœã«ã€ããŠã¯æžå°ãããããã§å
ã³ããã®æžå°ã¯ããããååšããå Žåã«ã¯ãäŸ
ç¶ãšããŠé©åºŠãªãŸãŸã§ããïŒäŸNo.ïŒã®èªå°äœã
4.5ã29mgïŒKg泚å°åŸã«â20ïŒ ã®æ倧å€ïŒã ãããã®çµæã¯ç¬ã«ãããå¿èè¡ç®¡ã®èæ§ãæº
足ãªãã®ã§ããããšã瀺ããã®ã§ãããäœæ ãªã
ã°ããããã®çµæãå¿èã®æµéã®é©åºŠãªæžå°ã«é
å®ããããã®ã§ãããä»æ¹å¿çå±€ã®åçž®åãåçž®
æã®åèå§ããã³å¿ææ°ã¯å€æ§ã«å€åããããã§
ããã ïŒ é»æ°ççåŠçè©Šéš æå€§é »åºŠè©Šéšãå®æœããããšã«ãããæ¬çºæã®
èªå°äœãå«æãã溶液äžã«å ¥ãããåé¢ããã¢ã«
ã¢ããã®å¿è³ã®åçž®ãã²ãèµ·ããããšãã§ããæ
倧åºæ¿é »åºŠã調ã¹ãã枬å®ã¯è©²èªå°äœã®æº¶æ¶²ãžã®
å°å ¥åïŒå¯Ÿç §æéïŒã次ãã§å°å ¥åŸã«è¡ãªã€ãã è¡šïŒã¯æ¬çºæã«ããåèªå°äœ10mgïŒã®æ¿åºŠã«
察ããŠçããæå€§é »åºŠã®æžå°å²åïŒïŒ ïŒã瀺ãã
ã®ã§ãããåŸãããçµæã¯æ¬çºæã«ããèªå°äœã
å¿è³ã®åºæ¿ç¡åå¿æéã12ã56ïŒ å¢å ãããããš
ã瀺ããŠãããè¡šïŒ äŸ ÎïŒ æ倧åºæ¿é »åºŠ ïŒ â30 ïŒ â56 ïŒ â53 ïŒ â27 ïŒ â12 ïŒ â46 ïŒ â45 ïŒ â ïŒ â48 10 â15 11 â52 12 â35 13 â44 14 â40 15 â40 16 â28 17 â32 18 â45 19 â52 ããã«ãé»æ°ççåŠçè©Šéšã¯ãå¯éããèžéã
æããããã³ããã«ãã¿ãŒã«ã§éº»é ããç¬ã«ã€ã
ãŠãçµç®çãªéèããã³åèæ段ã«ããå¿è窩ã«
å°å ¥ãããå極æ§ã®ã«ããŒãã«ãŒé»æ¥µã«ãã€ãŠè¡
ãªãããããã«ãã€ãŠæŽèªåæ§ïŒsinusal
automaticityïŒãå¿èå ã«äŒå°æéãããã³å¹æ
çãã€æ©èœçãªå¿èã®ç¡åå¿æéã枬å®ããã é»æ°ççåŠçãªèª¿æ»ã®éã該èªå°äœã¯åçšéã«
察ããŠïŒåéããã³30åééã§éèå ã«æ³šå°ã
ããçš®ã ã®ãã©ã¡ãŒã¿ãŒã®æž¬å®ã¯ãæåã®çšé
ïŒå¯Ÿç §æéïŒã®æ³šå°åããã³è©²ç©è³ªã®åçšéã®æ³š
å°åŸ10ã28åçµéããåŸã«å®æœãããæŽèªåæ§ã¯
é¡èã«ã¯äœäžãããå¿è³ãšæ¿å®€çµç¯ãšã®éã®äŒå°
é床ããŸãé¡èã«ã¯äœäžããªãããšã瀺ãããã
ä»æ¹ãäŒå°ã¯HisâPurkinjeç³»ã«ãããŠ4.5mgïŒKg
ã®çšéæéããé ãããããã®ãã©ã¡ãŒã¿ãŒã¯
VaughanâWilliamsã°ã«ãŒãïŒãããžã³é¡äŒŒïŒ
ã®æäžæŽèæè¬ã®å¹æã«éåžžã«ç¹åŸŽçãªãã®ã§ã
ããå¹æçãªå¿è³ããã³å¿å®€ã®ç¡åå¿æéã¯æäž
ããçšéã«æ¯äŸããŠé·ããªããä»æ¹ãæ¿å®€ã®çµç¯
æ§ã®æ©èœçç¡åå¿æéã ãã¯é©åºŠã«é·ããªãããŸ
ããã®å¹æã¯èª¿æ»ããçšéã®ç¯å²å ã§æ倧é«å¹³éš
ã«æ¥éã«å°éããã ïŒ æäžæŽèè©Šéš æ¬çºæã®èªå°äœã¯ã©ããã«ã€ããŠã¢ã³ããã³ã
çšããè©Šéšã«ãããŠäœ¿çšãããããã®è©Šéšã®ãã
ã«ã麻é ããã©ãããã¢ã³ããã³ã®éèå çæµ
ïŒç¡é žã¢ã³ããã³ã®æº¶æ¶²ïŒ15mgïŒïŒçæµã®é
床ïŒ0.4mgïŒminïŒã«ããäžæ¯ããããã®éãã®
å¿é»å³ããã€ãšèšé²ãããäžå®ã®é床ã§çæµããŠ
ããéãå¿å®€äžæŽèã®æ§çžãåããã®ã«èŠããæ
éãé£ç¶çãªå¿å®€æå€åçž®ïŒESVïŒãå¿å®€é »æ
ïŒTVïŒããã³å¿å®€çŽ°åïŒFVïŒã枬å®ããã åç©ã¯å¯Ÿç §çŸ€ïŒæªåŠçïŒãšåŠç矀ïŒçš®ã ã®çš
éïŒã«åãããçµæã¯ãå¯Ÿç §çŸ€ã«é¢ããŠåŠç矀ã«
ãããäžæŽèã®æ§çžãåããæéã®å»¶é·å²å
ïŒïŒ ïŒãšããŠç€ºããããããæ ããã®äžæŽèæ§çž
æéã®å»¶é·ã¯ã¢ã³ããã³ã®äžæŽèã®å¹æã«åãã
å¿çå±€ã®é²åŸ¡ã«çžåœããã®ã§ããã äžã®è¡šïŒã¯æ¬çºæã®çš®ã ã®èªå°äœã«ã€ããŠåŸã
ããçµæã瀺ããã®ã§ããã ãè¡šã æ¬çºæã®èªå°äœã®å¿èæ现å掻æ§ã¯ãããŠã¹ã«
ã€ããŠãããŒãœã³ïŒLawsonïŒè©ŠéšãçšããŠãJ.
W.LawsonïŒJ.Pharmacol.Exp.Therp.160ïŒ22â
31ïŒ1968ïŒãããã³C.NarcisseããAnn.Pharm.
Fr.37ã325â330ïŒ1979ïŒã«èšèŒãããæ¹æ³ã«åŸã€
ãŠç¢ºãããããã ããŠã¹ïŒçšéåœã20å¹ïŒã«ãã¯ãããã«ã ã§é£œ
åããé°å²æ°äžã«çœ®ã10ååã«è©²èªå°äœãè±è å
泚å°ãããåŒåžã®åæ¢ãèµ·ãããšçŽãèžéãéã
ïŒïŒã10ç§ïŒãå¿èã®ç¶æ ãå³ã¡å¿å®€ã®çŽ°åã®ååš
ãŸãã¯äžååšãããšãã¯ããã調ã¹ãããèªå°äœ
ã®æå¹çšé50ïŒED50ïŒã¯ç¡é žçŽ å¿å®€çŽ°åã«æããŠ
ããŠã¹ã®åæ°ãé²åŸ¡ããçšéã§ããã äžã®è¡šïŒã®çµæã¯ãæ¬çºæã®èªå°äœãè¯å¥œãªæ
现å掻æ§ãæããããšã瀺ããŠããã è¡š ïŒ èªå°äœ ED50ïŒmgïŒKgïŒ ïŒ 35 ïŒ 46 ïŒ 79 ïŒ 66 ïŒ 44 11 42.5 14 62 19 21.5 ããã«ãç¬ã«ã€ããŠCirculationïŒïŒïŒ1318
ïŒ1950ïŒã«èšèŒãããæ¹æ³ã«åŸã€ãŠè¡ãªã€ãããª
ã¹ïŒHarrisïŒè©Šéšã¯ãæ¬çºæã®èªå°äœãå¿å®€ã®
æå€åçž®ã®æžå°ãããããããšã瀺ããŠãããäŸ
ãšããŠãïŒåéåœãã®å¿å®€ã®æå€åçž®ã®åæ°ã¯è©²
çæç©ã®æ³šå°åŸïŒæéã®éãäŸ10èšèŒã®èªå°äœã®
å Žåã«ã¯çŽ50ïŒ æžå°ãããããã«ãæäžæŽèå¹æ
ïŒå¿çå±€ã®é²åŸ¡ïŒã¯æ³šå°ããçšéã®å€§ãããšå ±ã«
å¢å€§ããã æåŸã«ãæ¬çºæã®èªå°äœã¯ããŠãµã®ã®è§èïŒå±
ææ¥è§Šéº»é ïŒã«ã€ããŠè©Šéšãã¹ãèªå°äœãå«æã
ãç®è¬ã®ç¹çŒåŸã«ç¢ºãããããå±æçãªéº»é å¹æ
ãæãããäŸãã°ãäŸïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒã
ãã³ïŒã«èšèŒãããèªå°äœã¯æº¶æ¶²äž0.25ééïŒ ãŸ
ãã¯ïŒééïŒ ã§å±æ麻é è¬ïŒ100ïŒ éº»é ïŒã§ããã ãããã®çµæã¯ãæ¬çºæã®ïŒâã¢ãªãŒã«âïŒâ
ã¢ã«ã³ã·ãâãã©ãŸãŒã«ã®èªå°äœãæå©ãªæäžæŽ
èç¹æ§äžŠã³ã«é»æ°ççåŠçç¹æ§ããã³è¯å¥œãªè¡æµ
ååŠçèæ§ãæããå»è¬ããã³ç£å»è¬ãç¹ã«çš®ã
ã®åœ¢ã®å¿èäžæŽèã®æ²»çã«ããããããã®çšéã
å¯èœã«ããããšã瀺ããŠããã æ¬çºæã®èªå°äœããã³ãããã®è£œè¬çã«å容ã§
ããå¡©ã¯ã掻æ§æåãé©åœã«éžæãã補è¬çã«å
容ã§ããæ äœäžã«åžéãããŠããéåžžã®åœ¢æ ãäŸ
ãã°é å€ãã«ãã»ã«ãããŒã³ãžïŒãããŒãïŒãå
å€ãæ³šå ¥ã§ãã溶液ãŸãã¯ã·ãããã®åœ¢ã§æäžã
ãããšãã§ããã äŸãšããŠãé å€ã¯æ¬çºæã®èªå°äœãŸãã¯ãã®å¡©
ã®ïŒã€ãïŒãŸãã¯æ°çš®ã®åºäœåžéå€ãäŸãã°ã©ã¯
ããŒã¹ããã³ãããŒã«ã柱ç²ãããªããã«ãããª
ãã³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã¿ã«ã¯çãšæ··
åããããšã«ããäœãããšãã§ãããå¿ èŠãªã
ã°ãé å€ã¯ã掻æ§æåã®é£ç¶çãªæŸåºãŸãã¯é 延
å¹æã確å®ã«ããããããã«ãæ £çšæè¡ã«ããæ ž
ã®å²ãã«éãåãããããã€ãã®å±€ããæã€ãŠã
ãŠããããã³ãŒãã€ã³ã°ïŒå€ç®ïŒã¯äŸãã°ããªé ¢
é žããã«ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãŸãã¯ã»
ã«ããŒã¹ã¢ã»ããã¿ã¬ãŒãã®ïŒãŸãã¯æ°çš®ã®å±€ã
ãæã€ãŠããŠãããã æ¬çºæã®èªå°äœã¯ãŸã該èªå°äœãå¿ èŠãªãã°è£œ
è¬çã«å容ã§ããå¡©ã®åœ¢ã§æ°ŽãŸãã¯ã°ãªã»ããŒã«
äžã«æº¶è§£ãããããŠå¿ èŠã«å¿ããŠéåžžã®æ·»å å€ã
äŸãã°çå³ä»äžå€ããã³é žåé²æ¢å€ãæ·»å ããã
ãšã«ããåŸãããã·ããããŸãã¯é£²çšã§ãã溶液
ã®åœ¢ã§æäžããŠãããã æ³šå ¥ã§ãã溶液ã¯ããç¥ãããæè¡ãçšããŠäœ
ãããšãã§ãããããŠäŸãã°åèžçæ°Žãæ°Žåã¢ã«
ã¢ã«ã³ãŒã«ïŒhydroalcoholicïŒæº¶æ¶²ããããã¬ã³
ã°ãªã³ãŒã«çããŸãã¯ãã®ãããªæº¶åªã®æ··åç©äž
ã«æº¶è§£ãããæ¬çºæã®èªå°äœãŸãã¯ãã®è£œè¬çã«
å容ã§ããå¡©ã®ïŒã€ãå«æãã溶液ããæãããš
ãã§ãããå¿ èŠãªãã°ãé²è å€ã®ãããªé©åœãªæ·»
å å€ãæ·»å ããŠãããã çšé決å®ã¯æ²»çãããç¶æ ã®åããã³æ²»çãã
ãŠããæ£è ã«ããå€ããŠããããïŒæ¥ã«æäžãã
ãçšéã¯äžè¬ã«ãããžã³ã«ããæ²»çã®çšéã«å¹æµ
ãããããããç¶æ³ã«å¿ããŠéæ¥å»ã«ãã調æŽã
ãããšãã§ããã 以äžãæ¬çºæã詳现ã«ããã€ãã®ç¹å®ã®æ æ§ã«
é¢ããŠèª¬æããããåœæ¥è ã«ã¯æ¬çºæã®ç¹åŸŽãšç¯
å²ãéžè±ããããšãªãçš®ã ã®å€åœ¢ãããåŸãããš
ã¯æããã§ãããã
æ³ããã³ãããã®å»è¬çšéã«é¢ããã æ¬çºæã®ãã©ãŸãŒã«èªå°äœã¯äžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã·ãžã«åºã§ãããR1ãšR2ã¯åäžããŸãã¯ç°
ã€ãŠããŠããããããããæ°ŽçŽ ååãŸãã¯ã¢ã«ã
ã«åºããŸãã¯ããããçµåããçªçŽ ååããã³æŽ
ã«é žçŽ ååãå«æããããšã®ã§ããïŒãïŒå¡ç°ã
圢æããŠããããïœã¯ïŒãïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ãããã³ãã®è£œè¬çã«å容ã§ããå¡©ã§ã
ãã æ¬çºæã¯ãŸãçšæã«å ¥æã§ããå ¬ç¥ã®åæãã
é«åçã§äžè¬åŒïŒïŒã®èªå°äœã補é ã§ããæ¹æ³
ãæäŸããã æ¬çºæã¯ããã«ãŸãã¯å»è¬ç£å»è¬ã«ããããç¹
ã«å¿èäžæŽèã®æ²»çã«å¯Ÿããäžè¬åŒïŒïŒã®ãã©
ãŸãŒã«èªå°äœããã³ãããã®è£œè¬çã«å容ã§ãã
å¡©ã®çšéãæäŸããã äžè¬åŒïŒïŒäžã®Arã§ç€ºãããã¢ãªãŒã«åºã¯
ç¹ã«ïŒãŸãã¯ãã以äžã®ããã²ã³ååã§çœ®æãã
ãŠãããããšãã«åºã§ããåŸããã¯ããã²ã³å
åãŸãã¯çŽéãŸãã¯åæéã®ã¢ã«ãã«åºãäŸãã°
ã¡ãã«ããšãã«ãã€ãœãããã«ãïœâããã«ãïœ
âããã«ãã€ãœã¢ãã«çããŸãã¯ããšãã«ããã
ã¯ãã³ãžã«åºã瀺ãã R1ãšR2ãããããçµåããçªçŽ ååãšå ±ã«è€
çŽ ç°ã圢æãããšãã¯ããã®è€çŽ ç°ã¯ççŽ ååã«
ãã€ãŠå®å šã«ãããåºãäŸãã°ãããªãžãã«ãã
ããªãžã«åºçã§ããåŸãããã®è€çŽ ç°ã¯ãŸãïŒãŸ
ãã¯ãã以äžã®ç°ååãäŸãã°çªçŽ ããã³é žçŽ ã
å«æããããšãã§ããäŸãã°ãªããµãŸãªãžãã«ã
ããã©ãžãã«ãã¢ã«ããªãã«åºçã代衚çã§ã
ãã äžã®äžè¬åŒïŒïŒã«ãããŠãArã¯å¥œãŸããã¯
ããšãã«åºããããã¯ïŒãŸãã¯ãã以äžã®ããã²
ã³ååãäŸãã°å¡©çŽ ãèçŽ ãŸãã¯ããçŽ ã§çœ®æã
ããããšãã«åºãäŸãã°ïœâã¯ããããšãã«åºãŸ
ãã¯ïŒïŒïŒâãžã¯ããããšãã«åºã瀺ããã¯å¥œ
ãŸããã¯ããã²ã³ååãççŽ æ°ïŒãïŒã®äœçŽã¢ã«
ãã«åºãäŸãã°ã¡ãã«ããšãã«ãŸãã¯ãããã«
åºããããã¯ãã³ãžã«åºã瀺ããR1ãšR2ã¯å¥œãŸ
ããã¯ççŽ æ°ïŒãïŒã®äœçŽã¢ã«ãã«åºãäŸãã°ã¡
ãã«ãŸãã¯ã€ãœãããã«åºã瀺ããR1ãæ°ŽçŽ å
åã§ãããšãã¯R5ã¯ã¢ã«ãã«åºã§ããããŸãã¯
ãããšåå¿ã§ããããããã¯äžèšã®è€çŽ ç°ãç¹ã«
ãããªãžãã«ããããªãžã«ããªããµãŸãªã³ãžã
ã«ãããã©ãžãã«ãŸãã¯ã¢ã«ããªãã«åºãäžç·ã«
圢æãããïœã¯å¥œãŸããã¯ïŒãŸãã¯ïŒã§ããã æ¬çºæã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã«ã¯äžåŒïŒïŒããã³äžã®åŒïŒïŒ¡ïŒãšåŒ
ïŒïŒ¢ïŒã§ç€ºãããããã€ãã®åœ¢ãååšããã ïŒïŒããã³ïŒïŒ¡ïŒã®åœ¢ãæ¯é çã§ã¯ãã
ãããããå€éšçãªèŠå ã«ãã平衡ãïŒïŒ¢ïŒåœ¢
ã®æ¹ã«å€ããããšãããåŸããæ¬çºæã¯ãã¡ãã
äžã«ç€ºããïŒïŒãïŒïŒ¡ïŒããã³ïŒïŒ¢ïŒåœ¢ã®ã
ã¹ãŠã«ãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âã
ã©ãŸãŒã«ã«é¢ãããã®ã§ããã æ¬çºæã¯ãŸãäžã®äžè¬åŒïŒïŒã«ãã瀺ããã
ãã©ãŸãŒã«èªå°äœã®å¡©ãç¹ã«éåžžã®é±é žãŸãã¯æ
æ©é žãäŸãã°å¡©é žãç¡«é žãä¹³é žãã·ãŠãŠé žãã¯ãš
ã³é žããªã³é žãã¹ãã¢ãªã³é žããã¬ã€ã³é žãé ç³
é žçã該èªå°äœãšåå¿ãããããšã«ãã€ãŠåŸãã
ã補è¬çã«å容ã§ããå¡©ãæäŸãããã®ã§ããã
åå¿ã¯é žãšè©²èªå°äœãšãå®è³ªçã«ååŠéè«å²åã§
äžè¬ã«åå¿ãããéåžžã®æè¡ãçšããŠè¡ãªãããš
ãã§ããã æ¬çºæã«ããäžè¬åŒïŒïŒã§ç€ºããããã©ãŸãŒ
ã«èªå°äœã¯åŒïŒïŒ ïŒåŒäžãArãšïŒ²ã¯åŒïŒïŒã®å Žåãšåãæå³
ãæã€ïŒ ã®ãã©ãŸãã³ãããoå¡©åºæ§åªäœäžã§äžè¬åŒ
ïŒïŒ âïŒCH2ïŒoâNR1R2 ïŒïŒ ïŒåŒäžãã¯å¡©çŽ ãŸãã¯èçŽ ã®ãããªããã²ã³å
åã瀺ããïœïŒR1ããã³R2ã¯äžè¬åŒïŒïŒäžã§
å®çŸ©ãããšããã®ãã®ã§ããïŒ ã®ããã¢ã«ãã«ã¢ãã³ã§ã¢ã«ãã«åããããšã«ã
ã€ãŠè£œé ããããšãã§ããã åºçºç©è³ªãšããŠçšããããåŒïŒïŒã®ïŒâã¢ãª
ãŒã«âãã©ãŸãã³ã¯å ¬ç¥ã®ååç©ã§ãããæ £çšæ
è¡ãäŸãã°ãã¶ã»ã±ãã¹ããªãŒã»ãªãã»ããããµ
ã€ã¯ãªãã¯ã»ã³ã³ããŠã³ãºãWeissbergerïŒEd.ïŒ
Intersciences Publ.ïŒïŒ1964ïŒäžã«èšèŒãããæ¹
æ³ã«åŸã€ãŠäœãããšãã§ããã åŒïŒïŒã®ïŒâã¢ãªãŒã«ãã©ãŸãã³ãšåŒïŒïŒ
ã®ããã¢ã«ãã«ã¢ãã³ãšã®ã¢ã«ãã«ååå¿ã¯å¡©åº
æ§åªäœäžã§å¡©åºãäŸãã°æ°ŽçŽ åç©ãã¢ãããçé ž
å¡©ãŸãã¯ã¢ã«ã«ãªéå±ã¢ã«ã³ãã·ããŸãã¯ã¢ãã³
ã®ååšäžã§ãé©åœãªææ©æº¶åªäžã§è¡ãªãããšãã§
ããã ãã®åå¿ã¯äŸãã°æ°ŽçŽ åãããªãŠã ããããªãŠ
ã ã¢ãããæ°ŽçŽ åã«ãªãŠã ããããªãŠã ãšãã¬ãŒ
ããçé žã«ãªãŠã ãçé žãããªãŠã ããžãšãã«ã¢
ãã³ãããªãšãã«ã¢ãã³çã®ååšäžã§ããžã¡ãã«
ãã«ã ã¢ããããžã¡ãã«ã¹ã«ããã·ãããžãªããµ
ã³ãããã©ããããã©ã³ãã¡ã¿ããŒã«ãŸãã¯ãšã¿
ããŒã«ã®ãããªã¢ã«ã³ãŒã«ãããã³ã¢ã»ãã³ã®å
ããéžãã 溶åªäžã§è¡ãªãããšãã§ããã溶åªã
ã¢ã«ã³ãŒã«ã®ãšãã¯ãå¡©åºãšããŠã¯çžåœããã¢ã«
ã³ãã·ããäŸãã°ãšã¿ããŒã«äžã®ãããªãŠã ãšã
ãã·ããçšããããšã奜ãŸãããæ¬çºæã«ãã
ã°ã奜ãŸããã¯ãžã¡ãã«ãã«ã ã¢ããäžã®æ°ŽçŽ å
ãããªãŠã ããžãªããµã³äžã®çé žå¡©ãŸãã¯ãšã¿ã
ãŒã«äžã®ãããªãŠã ãšããã·ããçšããããã åå¿ã¯åšå²æž©åºŠã§èµ·ããããåå¿ãä¿é²ããã
ãã«åå¿æ··åç©ã30ã100âã奜ãŸããã¯40ã70
âã®æž©åºŠã«å ç±ããããšã奜ãŸããã æ¬çºæã®è£œæ³ã«ããã奜ãŸããæ¹æ³ã«ããã°ã
åŒïŒïŒã®ãã©ãŸãã³ã¯çªçŽ é°å²æ°äžã§ææ©æº¶æš¹
ã«æº¶è§£ãããå¡©åºãäŸãã°æ°ŽçŽ åãããªãŠã ãç
é žã«ãªãŠã ãŸãã¯ãããªãŠã ã¢ãããæ·»å ããã
æ··åç©ã¯æ¬¡ãã§å°ãå ç±ããããããŠåŒïŒïŒã®
ããã¢ã«ãã«ã¢ãã³ãé£ç¶çã«æ·»å ãããã溶åª
ã¯æžå§äžã§èžçºã«ããé€å»ãããåŸãããçæç©
ã¯éåžžã®ã¢ã·ãâå¡©åºãŸãã¯ã¯ãããã°ã©ãæœåº
æè¡ãçšããŠç²Ÿè£œãããã æ¬çºæã®æ¹æ³ã«åŸã€ãŠåŒïŒïŒã®ãã©ãŸãã³ã®
ã¢ã«ãã«åãè¡ãªãããã«çšããåŒïŒïŒã®ãã
ã¢ã«ãã«ã¢ãã³ã¯äžè¬ã«ã¯ãããã®å¡©é žå¡©ã®åœ¢ã§
åæ¥çã«å ¥æããããšãã§ããã䜿çšãããšã
ã¯ããããã®å¡©é žå¡©ãçžåœããå¡©åºã«å€ããããš
ã奜ãŸããããããã¯Fieser ïŒ FieserïŒ
Reagents for Organic SynthesisïŒNo.ïŒ
John Wiley ïŒ SonsïŒ1974ïŒã«èšèŒãããæ¹
æ³ã«åŸã€ãŠãããã®å¡©é žå¡©ãçé žã«ãªãŠã ã§é£œå
ãã溶液ã«æº¶ããã次ãã§æœåºããããšã«ãã€ãŠ
è¡ãªãã âïŒïŒâã¯ãããšãã«ïŒâãžã¡ãã«ã¢ãã³ã
âïŒïŒâã¯ãããããã«ïŒâãžã¡ãã«ã¢ãã³ãŸãã¯
âïŒïŒâã¯ãããšãã«ïŒâãžã€ãœãããã«ã¢ã
ã³ããŸãã¯è€çŽ ç°åŒããã¢ã«ãã«ã¢ãã³ãäŸãã°
âïŒïŒâã¯ãããšãã«ïŒâãããªãžã³ãâïŒïŒ
âã¯ãããšãã«ïŒâãããªãžã³ãâïŒïŒâã¯ãã
ãããã«ïŒâã¢ã«ããªã³ãâïŒïŒâã¯ããããã
ã«ïŒâãããªãžã³çã§ããæ¬çºæã«ãã䜿çšãã
åŸãæçšãªããã¢ã«ãã«ã¢ãã³ã®äŸãšããŠç¹ã«å
æããããšãã§ããã æ¬çºæã®ä»ã®è£œæ³ã«ããã°ãäžè¬åŒïŒïŒã®ã
ã©ãŸãŒã«èªå°äœã¯äžè¬åŒïŒïŒ ïŒåŒäžãArãšïŒ²ã¯åŒïŒïŒã®å Žåãšåãæå³
ããã€ïŒ ã§ç€ºããããšãã«ã¢ãã€ã«ã¢ã»ããŒãããäœã
ããšãã§ããããã¯åŒïŒïŒ HOâïŒCH2ïŒoâNR1R2 ïŒïŒ ïŒåŒäžãïœïŒR1ããã³R2ã¯åŒïŒïŒã®å Žåãš
åãæå³ããã€ïŒ ã§ç€ºãããã¢ããã¢ã«ã³ãŒã«ãçšãããšã¹ãã«
亀æåå¿ã«ãã€ãŠå€æããããšã«ããåŒïŒïŒ ã®ååç©ãåŸãé žåªäœäžã®ããã©ãžã³ãçšããŠç°
åãè¡ãªããäžè¬åŒïŒïŒã®èªå°äœãçæãã
ãã åŒïŒïŒã®ãšãã«ã¢ãã€ã«ã¢ã»ããŒãã®åŒ
ïŒïŒã®ã±ãã³ãšã¹ãã«ãžã®äº€æãå¯èœã«ãããš
ã¹ãã«äº€æåå¿ã¯å¥œãŸããã¯å ±æ²žèžçãå¯èœã«ã
ã溶åªäžã§å ç±ããããšã«ãã€ãŠè¡ãªããããã
ãã«ãé žè§Šåªã®ååšäžã«åå¿ãè¡ãªãããšã奜ãŸ
ããã溶åªã¯äŸãã°ãã«ãšã³ãŸãã¯ãã·ã¬ã³ã®ã
ããªçåæ°ŽçŽ ã§ããåŸãã é žåªäœãäŸãã°æ¿å¡©é žãŸãã¯ç¡«é žåªäœäžã®ãã
ã©ãžã³ãçšããç°ååå¿ã¯H.J.Backer ïŒ W.
MeierïŒRec.Trav.Chim.P.B.ïŒ45ïŒ428ïŒ1926ïŒ
ã®æ¹æ³ãšé¡äŒŒããæ¹æ³ã«åŸã€ãŠè¡ãªãããšãã§ã
ãã 次ã®äŸã¯ãã®ç¯å²ãéå®ããããšãªãæ¬çºæã
äŸç€ºãããã®ã§ããã äŸ ïŒ ïŒâïœâã¯ããããšãã«âïŒâãžã¡ãã«ã¢ããã
ãããã·âãã©ãŸãŒã«ã®è£œé ãžãªããµã³70mläžã®ïŒâïœâã¯ããããšãã«â
ãã©ãŸãã³9.5ïœãæªææ©ã枩床èšãåçž®åšãæµ
管ããã³çªçŽ å ¥å£ãåãã500ml容ãã©ã¹ã³äžã«
å ¥ãããçªçŽ é°å²æ°äžã§ããããéæµãã次ãã§
çé žã«ãªãŠã ïŒïœãå ãããéæµäžã§ïŒæéå ç±
ããåŸãåå¿åªäœãéæµãã€ã¥ããªããïŒâãžã¡
ãã«ã¢ããâïŒâã¯ãããããã³7.2ïœãå ããã
æ·»å ã¯45åéé£ç¶çã«è¡ãªããããæ··åç©ãçŽïŒ
æééæµãã€ã¥ãã次ãã§ã¢ã·ãâå¡©åºæœåºãæ £
çšæè¡ãçšããŠæžå§èžçºã«ãã溶åªã®é€å»åŸã«è¡
ãªã€ãã ãããµã³ã次ãã§ã€ãœãããã«ãšãŒãã«äžã§å
çµæ¶ããåŸãïŒâïœâã¯ããããšãã«âïŒâãžã¡
ãã«ã¢ããããããã·âãã©ãŸãŒã«6.6ïœãåŸã
ïŒåç47ïŒ ïŒã èç¹ 114âïŒã€ãœãããã«ãšãŒãã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒÎœïŒ3130ïŒ3100ïŒ 1510ïŒ1490cm-1ã NMRã¹ãã¯ãã«ïŒCDCl3ïŒÎŽïŒ1.7ã2.7ïŒ4HïŒïŒ 2.2ïŒïœïŒ6HïŒïŒ4.0ïŒïœïŒ2HïŒïŒ 5.8ïŒïœïŒ1HïŒïŒ7.3ïŒïœïŒ4HïŒïŒ 11.2ïŒïŒ³ïŒ1HïŒppm äžèšååç©ã®ãã¬ã€ã³é žå¡©ã¯æ £çšæè¡ã«åŸã€ãŠ
ãšã¿ããŒã«äžã§ãã¬ã€ã³é žãšåå¿ãããããšã«ã
ã€ãŠè£œé ããã èç¹ 155â äŸ ïŒ ïŒâããšãã«âïŒâã¡ãã«âïŒâãããªãžããšã
ãã·âãã©ãŸãŒã«ã®è£œé äŸïŒãšåæ§ã«ãïŒâããšãã«âïŒâãã©ãŸãã³
ïŒïœããžãªããµã³60mlã«æº¶ãããçªçŽ é°å²æ°äžã§
éæµããªããå ç±ãã次ãã§çé žã«ãªãŠã 3.9ïœ
ãå ãããåå¿æ··åç©ãéæµããªããçŽïŒæéä¿
ã¡ã次ãã§ïŒ®âïŒïŒâã¯ãããšãã«ïŒãããªãžã³
13ïœãé£ç¶çã«å ããã åå¿åŸïŒæéãæ··åç©ãéæµããªããä¿ã¡ã次
ãã§æº¶åªãæžå§èžçºã«ããé€å»ããããã«æœåºã
è¡ãªã€ãã ã·ã¯ããããµã³äžã§åçµæ¶ããåŸãïŒâããšã
ã«âïŒâã¡ãã«âïŒâãããªãžãã¡ããã·âãã©
ãŸãŒã«3.5ïœãåŸãïŒåç26ïŒ ïŒã èç¹ïŒ88âïŒã·ã¯ããããµã³ïŒ èå±€ã¯ãããã°ã©ãã€âïŒTLCïŒïŒ RïŒ0.4ïŒé ¢é žãšãã«ïŒ10ïŒ ãžãšãã«ã¢ãã³ïŒ æ £çšæè¡ã«ããåŸãçžåœãããã¬ã€ã³é žå¡©ã¯è
ç¹158ã159âïŒãšã¿ããŒã«ïŒãæããŠããã äŸ ïŒ ïŒâã¯ããããšãã«âïŒâãããªãžãããããã·
âãã©ãŸãŒã«ã®è£œé ïŒâïœâã¯ããããšãã«âãã©ãŸãã³19.4ïœã
ãã³ç¡æ°Žãžã¡ãã«ãã«ã ã¢ãã60mlãå¡©åã«ã«ã·
ãŠã 管ãæããåçž®åšãæµç®¡ã枩床èšããã³çªçŽ
å ¥å£ãåãã500ml容ãã©ã¹ã³ã«å ¥ããã次ãã§
溶液äžã«çªçŽ ã泡ç«ãŠãªããéãããšã«ãã溶液
ãè±æ°ãããæ··åç©ãçŽïŒâã«å·åŽããã€ãã§æ°Ž
çŽ åãããªãŠã 2.8ïœãå ãããæ··åç©ã®æž©åºŠã
åšå²æž©åºŠã«ãã©ããã€ãã§40âã«é£ç¶çã«å ç±ã
ããïŒâã¯ãããããã«âãããªãžã³17.4ïœã滎
å ããçŽ10æéåå¿ãããã 溶åªãæžå§èžçºãããåŸãã¢ã·ãâå¡©åºæœåºã
ããã³ã€ãœãããããŒã«äžã§ã®åçµæ¶ãè¡ãªãã
ãšã«ããïŒâïœâã¯ããããšãã«âïŒâãããªãž
ãããããã·âãã©ãŸãŒã«10.7ïœãåŸãïŒåç30
ïŒ ïŒãããã«ã粟補äžã«åæïŒâïœâã¯ããããš
ãã«âïŒâãã©ãŸãã³ã®çŽ25ïŒ ããã³ïŒæ¬¡çæç©
ãšããŠïŒâïœâã¯ããããšãã«âïŒâãããªãžã
ãããã«âãã©ãŸãã³çŽïŒïœãååããã èç¹ïŒ140âïŒã€ãœãããããŒã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒïŒÎœïŒ3250ïŒ1510cm
âïŒ NMRã¹ãã¯ãã«ïŒCDCl3ïŒïŒÎŽïŒ1.6ïŒ6HïŒïŒ2.1
ïŒ2HïŒïŒ 2.6ïŒ6HïŒïŒ4.3ïŒïœïŒ2HïŒïŒ 6.2ïŒïœïŒ1HïŒïŒ7.8ïŒïœïŒ4HïŒppm äŸ ïŒ ïŒâããšãã«âïŒâã¡ãã«âïŒâã¢ã«ããªããšã
ãã·âãã©ãŸãŒã«ã®è£œé äŸïŒã®æ¹æ³ãçšããŠãïŒâããšãã«âïŒâãã©
ãŸãã³ïŒïœããžãªããµã³60mlã«æº¶ããããããã
éæµããªããå ç±ããçé žã«ãªãŠã 4.1ïœãå ãã
ã€ãã§é£ç¶çã«ïŒ®âïŒïŒâã¯ãããšãã«ïŒã¢ã«ã
ãªã³7.8ïœãå ããã åå¿ãçµäºãããšããæœåºããã³ã€ãœãããã
ãŒã«äžã§ã®åçµæ¶ãè¡ãªããïŒâããšãã«âïŒâ
ã¡ãã«âïŒâã¢ã«ããªããšããã·ãã©ãŸãŒã«5.1
ïœãåŸãïŒåç36ïŒ ïŒã èç¹ïŒ100âïŒã€ãœãããããŒã«ïŒ TLCïŒRïŒ0.60ïŒé ¢é žãšãã«ïŒ10ïŒ ãžãšãã«ã¢
ãã³ïŒ æ £çšæè¡ã«ãããšã¿ããŒã«äžã§ãã¬ã€ã³é žãšå
å¿ãããããšã«ãã€ãŠäœã€ãçžåœãããã¬ã€ã³é ž
å¡©ã¯èç¹156âãæããŠããã äŸ ïŒ ïŒâããšãã«âïŒâã¢ã«ããªããšãã·ãâãã©ãŸ
ãŒã«ã®è£œé å ±æ²žèžçè£ çœ®ãšæµç®¡ãåãã250ml容ãã©ã¹ã³
äžã§ãã³ãŸã€ã«é ¢é žãšãã«9.6ïœããã³ïŒ®âïŒïŒâ
ããããã·ãšãã«ïŒã¢ã«ããªã³19.7ïœããã«ãšã³
100mlã«æº¶ãããã ããã沞ç¹ãŸã§å ç±ãããã«ãšã³âãšã¿ããŒã«
å ±æ²žæ··åç©ãèžçããåæã«çŽç²ãªãã«ãšã³ãå
ãããåå¿ã¯äºå®äžçŽïŒæéåŸã«å®å šã«çµäºã
ãããã«ãšã³ãèžçæ°Žã§æŽããã€ãã§å¡©åã«ã«ã·
ãŠã 飜åæ°Žã§æŽã€ãåŸãç¡«é žãããªãŠã äžã§ä¹Ÿç¥
ãã也ç¥ãããŸã§èžçºãããããã®ããã«ããŠã¢
ã«ããªããšãã«ãã³ãŸã€ã«ã¢ã»ããŒã12.4ïœãé»
è²ãæ²¹ã®åœ¢ã§åŸãïŒåç90ïŒ ïŒã æ°Žåããã©ãžã³0.3ïœç¡æ°Žãšã¿ããŒã«15mlãã
ã³æ¿å¡©é ž1.6mlã100ml容ãã©ã¹ã³ã«å ¥ããããã
ãéæµæž©åºŠã«å ç±ããäžèšã®ã¢ã«ããªããšãã«ã
ã³ãŸã€ã«ã¢ã»ããŒã1.4ïœãå ãããæ··åç©ãé
æµããªããçŽïŒæéä¿ã¡ãåå¿ãäºå®äžå®å šã«çµ
äºãããããšã¿ããŒã«ãæžå§èžçãããã€ãã§å
å¿çæç©ãæ°Žã§æŽããã¯ãããã«ã ã§æœåºããïŒ
âãšããã³âïŒâããšãã«âãã©ãŸãŒã«çŽ0.1ïœ
ãåé¢ãããæ°Žæ§çžãã¢ã«ã«ãªæ§ã«ããã€ãã§ã¯
ãããã«ã ã§æœåºããããšã«ããïŒâããšãã«â
ïŒâã¢ã«ããªããšããã·âãã©ãŸãŒã«0.5ïœãåŸ
ãïŒåç36ïŒ ïŒã èç¹ïŒ100âïŒã€ãœãããããŒã«ïŒ IRã¹ãã¯ãã«ïŒããžãšãŒã«ïŒÎœïŒ3260ïŒ1595ïŒ 1510cm-1ã äŸ ïŒã23 äŸïŒã®æ¹æ³ãçšããŠããã ãåæãã©ãŸãã³ã
ãã³ããã¢ã«ãã«ã¢ãã³ãé©åœã«å€æŽããŠäžè¡šã«
瀺ããçæç©ããã³ãããã®å¡©ãåŸãããããã®
ç¹æ§ïŒèç¹ãåçµæ¶æº¶åªããã³10ïŒ ãžãšãã«ã¢ã
ã³ãå ããé ¢é žãšãã«ããæã溶é¢å€ã«ããèè
ã¯ãããã°ã©ãã€ãŒïŒããŸãåè¡šã«ç€ºãããŠã
ãã ãè¡šã ãè¡šã ãè¡šã æ¬çºæã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã«ã€ããŠè¡ãªã€ãè©äŸ¡ã¯è©²ååç©ãç£å»è¬
ããã³å»è¬ã«ãããŠæçšãªãã®ãšããèå³æ·±ãè¬
çåŠçãã€æ¯ç©åŠçç¹æ§ã瀺ããã æ¯ç©åŠçç¹æ§ æ¬çºæã®èªå°äœã®æ¥æ§æ¯æ§ã¯ããŠã¹ïŒ10å¹ãçš
éåœãéïŒå¹ããã³éïŒå¹ïŒã«å¯Ÿããçµå£æäž
ïŒP.O.ïŒäžŠã³ã«Litchfieldããã³WilcoxonïŒJ.
Pharmacol.ïŒ96ïŒ99â113ïŒ1949ïŒïŒã®æ¹æ³ã«åŸã€
ãèŽæ»çšé50ïŒLD50ïŒã®ç®å®ã«ãã調ã¹ããè¡šïŒ
ã¯æ¬çºæã®èªå°äœã®LD50å€ã瀺ããŠããã ããã€ããã®äºäŸã§ã¯ãLD50ã¯ãŸã該èªå°äœ
ã®è ¹è å 泚å°ïŒI.P.ïŒåŸã«èª¿ã¹ãããã åŸãããçµæãäžã«ç€ºãã ãè¡šã ãè¡šã è¬çåŠçç¹æ§ ïŒ å¿èè¡ç®¡ã®èæ§ å¿èè¡ç®¡ã®èæ§ã¯ãåé¢ããã¢ã«ã¢ããã®å¿
è³ã麻é ããã©ããããã³åãã麻é ããç¬ã«ã€
ããŠèª¿ã¹ãã ã¢ã«ã¢ããã®å¿è³ã«ã€ããŠã¯ã該詊æã¯ã¢ã«ã¢
ããã®å¿è³ã®å¿çå±€ã®åçž®å䞊ã³ã«å¿è³ã®åçž®ã®
é »åºŠã®æž¬å®ãå¯èœã«ããã济液ã®10ÎŒïœïŒmlã®æ¿
床ã§ã¯ãè©Šéšãããèªå°äœã¯äºååŠçå¯Ÿç §æéã«
é¢ããŠ15ã75ïŒ ã®åçž®é »åºŠã®æžå°ïŒå¹³åâ43.25
ïŒ ïŒãããããããåãæ¿åºŠã§ãåçž®åã¯å¯Ÿç §æ
éã«é¢ããŠïŒãâ80ïŒ å€åããïŒå¹³åå€åçâ
37.5ïŒ ïŒã 麻é ããã©ããã«ã€ããŠã¯ãïŒã25ïœïŒKgã®çš
éã§æäžãããæ¬çºæã®èªå°äœã¯å¿ææ°
ïŒcardiac frequencyïŒã®æžå°ïŒïŒã40ïŒ ïŒã倧å
èã®æµéã®æžå°ãããã³åçž®æã®åèå§ã®æžå°
ïŒïŒã60ïŒ ïŒããããããã 麻é ããç¬ã«ã€ããŠã¯ãè¡æµååŠçèæ§ã«é¢ã
ãŠåŸãçµæãäžã®è¡šã«èŠçŽãããè¡šïŒã¯äŸïŒãã
ã³ïŒã®èªå°äœã«å¯ŸããäºååŠçå¯Ÿç §æéã«é¢ãã
è¡æµååŠçãã©ã¡ãŒã¿ãŒã®å€åçïŒïŒ ïŒã瀺ãã
ã®ã§ããã ãããã®ãã©ã¡ãŒã¿ãŒã¯æ¬¡ã®æ段ã«ããèšé²ã
ããã â å§åã»ã³ãµãŒã«çµåããã«ããŒãã«ïŒåè
å§ãå·Šå¿å®€ã®å§åããã³ãã®ç¬¬ïŒèªå°äœdpïŒ
dtïŒ â 倧åèäžã®é»ç£æµéèšïŒå€§åèã®æµéïŒ â å¿é»èš â å·Šå¿å®€ã®å¿çå±€äžã«èšçœ®ããã¹ãã¬ã€ã³ã²
ãŒãžïŒã²ãã¿èšïŒïŒå¿çå±€ã®åçž®åïŒ è©²èªå°äœãçŽ30åæ¯ã«ïŒçšéã¥ã€éèå ã«æ³šå°
ãããããŠãããã®å¹æã泚å°çµäºåŸ ïŒæ³šå°ã®
æèŠæéã¯ïŒåïŒ20åçµéããŠãã枬å®ããã ãè¡šã åçž®å
(dpïŒdt) ïŒ âïŒ â30 â30 â38 â46
ïŒp
泚ïŒå¹æã¯äºååŠçå¯Ÿç §æéã«é¢ããå€
åç(ïŒ )ãšããŠè¡šããã
è¡šïŒã«ç€ºããçµæãããã³æ¬çºæã®ä»ã®èªå°äœ
ã«ã€ããŠåŸãããé¡äŒŒã®çµæã¯ãç¬ã«å¯ŸããŠæ¬¡ã®
ãããªè»œæžïŒç·©åïŒãããç¶æ ãããããããšã
瀺ããŠããã â åçž®æã®åèå§ã¯å€åããªãïŒäŸïŒããã³ïŒ
ã®èªå°äœïŒãããŸãã¯é©åºŠã«äœäžããïŒäŸïŒã
14ããã³19ã®èªå°äœïŒãããããäŸNo.ïŒã®èªå°
äœã«å¯ŸããŠã¯ãã®æžå°ã¯4.5mgïŒKgã®èç©çšé
åŸã«çŸãããã«ãããªãã â å¿ææ°ã¯å€åããªãïŒäŸïŒããã³19ã®èªå°
äœïŒãããŸãã¯é©åºŠã«æžå°ããïŒäŸïŒãïŒãã
ã³14ã®èªå°äœïŒã â å¿èã®æµéã¯ãã¹ãŠã®å Žåã«äœäžããããã
ããªãããïŒmgïŒKgããå€ãèç©çšéïŒäŸïŒã
ïŒããã³19ã®èªå°äœïŒãŸãã¯ïŒïœïŒKgããå€ã
èç©å®¹éïŒäŸïŒã®èªå°äœïŒã«ãã€ãŠãã20ïŒ ã®
æžå°ã«éããçšåºŠã§ããããããã®ãããªå€å
ïŒäœäžïŒã¯äŸç¶ãšããŠé©åºŠãªãŸãŸã§ããã â å¿å®€ã®å¿çå±€ã®åçž®åã¯ãäŸNo.ïŒã®èªå°äœã®
泚å°åŸã«ã¯å¢å ããäŸNo.ïŒããã³14ã®èªå°äœã«
ã€ããŠã¯é¡èã«å€åããããšã¯ãªããäŸNo.ïŒã
ãã³19ã®èªå°äœã«ã€ããŠã¯æžå°ãããããã§å
ã³ããã®æžå°ã¯ããããååšããå Žåã«ã¯ãäŸ
ç¶ãšããŠé©åºŠãªãŸãŸã§ããïŒäŸNo.ïŒã®èªå°äœã
4.5ã29mgïŒKg泚å°åŸã«â20ïŒ ã®æ倧å€ïŒã ãããã®çµæã¯ç¬ã«ãããå¿èè¡ç®¡ã®èæ§ãæº
足ãªãã®ã§ããããšã瀺ããã®ã§ãããäœæ ãªã
ã°ããããã®çµæãå¿èã®æµéã®é©åºŠãªæžå°ã«é
å®ããããã®ã§ãããä»æ¹å¿çå±€ã®åçž®åãåçž®
æã®åèå§ããã³å¿ææ°ã¯å€æ§ã«å€åããããã§
ããã ïŒ é»æ°ççåŠçè©Šéš æå€§é »åºŠè©Šéšãå®æœããããšã«ãããæ¬çºæã®
èªå°äœãå«æãã溶液äžã«å ¥ãããåé¢ããã¢ã«
ã¢ããã®å¿è³ã®åçž®ãã²ãèµ·ããããšãã§ããæ
倧åºæ¿é »åºŠã調ã¹ãã枬å®ã¯è©²èªå°äœã®æº¶æ¶²ãžã®
å°å ¥åïŒå¯Ÿç §æéïŒã次ãã§å°å ¥åŸã«è¡ãªã€ãã è¡šïŒã¯æ¬çºæã«ããåèªå°äœ10mgïŒã®æ¿åºŠã«
察ããŠçããæå€§é »åºŠã®æžå°å²åïŒïŒ ïŒã瀺ãã
ã®ã§ãããåŸãããçµæã¯æ¬çºæã«ããèªå°äœã
å¿è³ã®åºæ¿ç¡åå¿æéã12ã56ïŒ å¢å ãããããš
ã瀺ããŠãããè¡šïŒ äŸ ÎïŒ æ倧åºæ¿é »åºŠ ïŒ â30 ïŒ â56 ïŒ â53 ïŒ â27 ïŒ â12 ïŒ â46 ïŒ â45 ïŒ â ïŒ â48 10 â15 11 â52 12 â35 13 â44 14 â40 15 â40 16 â28 17 â32 18 â45 19 â52 ããã«ãé»æ°ççåŠçè©Šéšã¯ãå¯éããèžéã
æããããã³ããã«ãã¿ãŒã«ã§éº»é ããç¬ã«ã€ã
ãŠãçµç®çãªéèããã³åèæ段ã«ããå¿è窩ã«
å°å ¥ãããå極æ§ã®ã«ããŒãã«ãŒé»æ¥µã«ãã€ãŠè¡
ãªãããããã«ãã€ãŠæŽèªåæ§ïŒsinusal
automaticityïŒãå¿èå ã«äŒå°æéãããã³å¹æ
çãã€æ©èœçãªå¿èã®ç¡åå¿æéã枬å®ããã é»æ°ççåŠçãªèª¿æ»ã®éã該èªå°äœã¯åçšéã«
察ããŠïŒåéããã³30åééã§éèå ã«æ³šå°ã
ããçš®ã ã®ãã©ã¡ãŒã¿ãŒã®æž¬å®ã¯ãæåã®çšé
ïŒå¯Ÿç §æéïŒã®æ³šå°åããã³è©²ç©è³ªã®åçšéã®æ³š
å°åŸ10ã28åçµéããåŸã«å®æœãããæŽèªåæ§ã¯
é¡èã«ã¯äœäžãããå¿è³ãšæ¿å®€çµç¯ãšã®éã®äŒå°
é床ããŸãé¡èã«ã¯äœäžããªãããšã瀺ãããã
ä»æ¹ãäŒå°ã¯HisâPurkinjeç³»ã«ãããŠ4.5mgïŒKg
ã®çšéæéããé ãããããã®ãã©ã¡ãŒã¿ãŒã¯
VaughanâWilliamsã°ã«ãŒãïŒãããžã³é¡äŒŒïŒ
ã®æäžæŽèæè¬ã®å¹æã«éåžžã«ç¹åŸŽçãªãã®ã§ã
ããå¹æçãªå¿è³ããã³å¿å®€ã®ç¡åå¿æéã¯æäž
ããçšéã«æ¯äŸããŠé·ããªããä»æ¹ãæ¿å®€ã®çµç¯
æ§ã®æ©èœçç¡åå¿æéã ãã¯é©åºŠã«é·ããªãããŸ
ããã®å¹æã¯èª¿æ»ããçšéã®ç¯å²å ã§æ倧é«å¹³éš
ã«æ¥éã«å°éããã ïŒ æäžæŽèè©Šéš æ¬çºæã®èªå°äœã¯ã©ããã«ã€ããŠã¢ã³ããã³ã
çšããè©Šéšã«ãããŠäœ¿çšãããããã®è©Šéšã®ãã
ã«ã麻é ããã©ãããã¢ã³ããã³ã®éèå çæµ
ïŒç¡é žã¢ã³ããã³ã®æº¶æ¶²ïŒ15mgïŒïŒçæµã®é
床ïŒ0.4mgïŒminïŒã«ããäžæ¯ããããã®éãã®
å¿é»å³ããã€ãšèšé²ãããäžå®ã®é床ã§çæµããŠ
ããéãå¿å®€äžæŽèã®æ§çžãåããã®ã«èŠããæ
éãé£ç¶çãªå¿å®€æå€åçž®ïŒESVïŒãå¿å®€é »æ
ïŒTVïŒããã³å¿å®€çŽ°åïŒFVïŒã枬å®ããã åç©ã¯å¯Ÿç §çŸ€ïŒæªåŠçïŒãšåŠç矀ïŒçš®ã ã®çš
éïŒã«åãããçµæã¯ãå¯Ÿç §çŸ€ã«é¢ããŠåŠç矀ã«
ãããäžæŽèã®æ§çžãåããæéã®å»¶é·å²å
ïŒïŒ ïŒãšããŠç€ºããããããæ ããã®äžæŽèæ§çž
æéã®å»¶é·ã¯ã¢ã³ããã³ã®äžæŽèã®å¹æã«åãã
å¿çå±€ã®é²åŸ¡ã«çžåœããã®ã§ããã äžã®è¡šïŒã¯æ¬çºæã®çš®ã ã®èªå°äœã«ã€ããŠåŸã
ããçµæã瀺ããã®ã§ããã ãè¡šã æ¬çºæã®èªå°äœã®å¿èæ现å掻æ§ã¯ãããŠã¹ã«
ã€ããŠãããŒãœã³ïŒLawsonïŒè©ŠéšãçšããŠãJ.
W.LawsonïŒJ.Pharmacol.Exp.Therp.160ïŒ22â
31ïŒ1968ïŒãããã³C.NarcisseããAnn.Pharm.
Fr.37ã325â330ïŒ1979ïŒã«èšèŒãããæ¹æ³ã«åŸã€
ãŠç¢ºãããããã ããŠã¹ïŒçšéåœã20å¹ïŒã«ãã¯ãããã«ã ã§é£œ
åããé°å²æ°äžã«çœ®ã10ååã«è©²èªå°äœãè±è å
泚å°ãããåŒåžã®åæ¢ãèµ·ãããšçŽãèžéãéã
ïŒïŒã10ç§ïŒãå¿èã®ç¶æ ãå³ã¡å¿å®€ã®çŽ°åã®ååš
ãŸãã¯äžååšãããšãã¯ããã調ã¹ãããèªå°äœ
ã®æå¹çšé50ïŒED50ïŒã¯ç¡é žçŽ å¿å®€çŽ°åã«æããŠ
ããŠã¹ã®åæ°ãé²åŸ¡ããçšéã§ããã äžã®è¡šïŒã®çµæã¯ãæ¬çºæã®èªå°äœãè¯å¥œãªæ
现å掻æ§ãæããããšã瀺ããŠããã è¡š ïŒ èªå°äœ ED50ïŒmgïŒKgïŒ ïŒ 35 ïŒ 46 ïŒ 79 ïŒ 66 ïŒ 44 11 42.5 14 62 19 21.5 ããã«ãç¬ã«ã€ããŠCirculationïŒïŒïŒ1318
ïŒ1950ïŒã«èšèŒãããæ¹æ³ã«åŸã€ãŠè¡ãªã€ãããª
ã¹ïŒHarrisïŒè©Šéšã¯ãæ¬çºæã®èªå°äœãå¿å®€ã®
æå€åçž®ã®æžå°ãããããããšã瀺ããŠãããäŸ
ãšããŠãïŒåéåœãã®å¿å®€ã®æå€åçž®ã®åæ°ã¯è©²
çæç©ã®æ³šå°åŸïŒæéã®éãäŸ10èšèŒã®èªå°äœã®
å Žåã«ã¯çŽ50ïŒ æžå°ãããããã«ãæäžæŽèå¹æ
ïŒå¿çå±€ã®é²åŸ¡ïŒã¯æ³šå°ããçšéã®å€§ãããšå ±ã«
å¢å€§ããã æåŸã«ãæ¬çºæã®èªå°äœã¯ããŠãµã®ã®è§èïŒå±
ææ¥è§Šéº»é ïŒã«ã€ããŠè©Šéšãã¹ãèªå°äœãå«æã
ãç®è¬ã®ç¹çŒåŸã«ç¢ºãããããå±æçãªéº»é å¹æ
ãæãããäŸãã°ãäŸïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒã
ãã³ïŒã«èšèŒãããèªå°äœã¯æº¶æ¶²äž0.25ééïŒ ãŸ
ãã¯ïŒééïŒ ã§å±æ麻é è¬ïŒ100ïŒ éº»é ïŒã§ããã ãããã®çµæã¯ãæ¬çºæã®ïŒâã¢ãªãŒã«âïŒâ
ã¢ã«ã³ã·ãâãã©ãŸãŒã«ã®èªå°äœãæå©ãªæäžæŽ
èç¹æ§äžŠã³ã«é»æ°ççåŠçç¹æ§ããã³è¯å¥œãªè¡æµ
ååŠçèæ§ãæããå»è¬ããã³ç£å»è¬ãç¹ã«çš®ã
ã®åœ¢ã®å¿èäžæŽèã®æ²»çã«ããããããã®çšéã
å¯èœã«ããããšã瀺ããŠããã æ¬çºæã®èªå°äœããã³ãããã®è£œè¬çã«å容ã§
ããå¡©ã¯ã掻æ§æåãé©åœã«éžæãã補è¬çã«å
容ã§ããæ äœäžã«åžéãããŠããéåžžã®åœ¢æ ãäŸ
ãã°é å€ãã«ãã»ã«ãããŒã³ãžïŒãããŒãïŒãå
å€ãæ³šå ¥ã§ãã溶液ãŸãã¯ã·ãããã®åœ¢ã§æäžã
ãããšãã§ããã äŸãšããŠãé å€ã¯æ¬çºæã®èªå°äœãŸãã¯ãã®å¡©
ã®ïŒã€ãïŒãŸãã¯æ°çš®ã®åºäœåžéå€ãäŸãã°ã©ã¯
ããŒã¹ããã³ãããŒã«ã柱ç²ãããªããã«ãããª
ãã³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã¿ã«ã¯çãšæ··
åããããšã«ããäœãããšãã§ãããå¿ èŠãªã
ã°ãé å€ã¯ã掻æ§æåã®é£ç¶çãªæŸåºãŸãã¯é 延
å¹æã確å®ã«ããããããã«ãæ £çšæè¡ã«ããæ ž
ã®å²ãã«éãåãããããã€ãã®å±€ããæã€ãŠã
ãŠããããã³ãŒãã€ã³ã°ïŒå€ç®ïŒã¯äŸãã°ããªé ¢
é žããã«ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãŸãã¯ã»
ã«ããŒã¹ã¢ã»ããã¿ã¬ãŒãã®ïŒãŸãã¯æ°çš®ã®å±€ã
ãæã€ãŠããŠãããã æ¬çºæã®èªå°äœã¯ãŸã該èªå°äœãå¿ èŠãªãã°è£œ
è¬çã«å容ã§ããå¡©ã®åœ¢ã§æ°ŽãŸãã¯ã°ãªã»ããŒã«
äžã«æº¶è§£ãããããŠå¿ èŠã«å¿ããŠéåžžã®æ·»å å€ã
äŸãã°çå³ä»äžå€ããã³é žåé²æ¢å€ãæ·»å ããã
ãšã«ããåŸãããã·ããããŸãã¯é£²çšã§ãã溶液
ã®åœ¢ã§æäžããŠãããã æ³šå ¥ã§ãã溶液ã¯ããç¥ãããæè¡ãçšããŠäœ
ãããšãã§ãããããŠäŸãã°åèžçæ°Žãæ°Žåã¢ã«
ã¢ã«ã³ãŒã«ïŒhydroalcoholicïŒæº¶æ¶²ããããã¬ã³
ã°ãªã³ãŒã«çããŸãã¯ãã®ãããªæº¶åªã®æ··åç©äž
ã«æº¶è§£ãããæ¬çºæã®èªå°äœãŸãã¯ãã®è£œè¬çã«
å容ã§ããå¡©ã®ïŒã€ãå«æãã溶液ããæãããš
ãã§ãããå¿ èŠãªãã°ãé²è å€ã®ãããªé©åœãªæ·»
å å€ãæ·»å ããŠãããã çšé決å®ã¯æ²»çãããç¶æ ã®åããã³æ²»çãã
ãŠããæ£è ã«ããå€ããŠããããïŒæ¥ã«æäžãã
ãçšéã¯äžè¬ã«ãããžã³ã«ããæ²»çã®çšéã«å¹æµ
ãããããããç¶æ³ã«å¿ããŠéæ¥å»ã«ãã調æŽã
ãããšãã§ããã 以äžãæ¬çºæã詳现ã«ããã€ãã®ç¹å®ã®æ æ§ã«
é¢ããŠèª¬æããããåœæ¥è ã«ã¯æ¬çºæã®ç¹åŸŽãšç¯
å²ãéžè±ããããšãªãçš®ã ã®å€åœ¢ãããåŸãããš
ã¯æããã§ãããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã·ãžã«åºã§ãããR1ãšR2ã¯åäžããŸãã¯ç°
ã€ãŠããŠããããããããæ°ŽçŽ ååãŸãã¯ã¢ã«ã
ã«åºããŸãã¯ããããçµåããçªçŽ ååããã³æŽ
ã«é žçŽ ååãå«æããããšã®ã§ããïŒãïŒå¡ç°ã
圢æããŠããããïœã¯ïŒãïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ããã³ãã®è£œè¬çã«å容ã§ããé žå¡©ã ïŒ Arãããšãã«åºãŸãã¯ïŒåãŸãã¯ãã以äž
ã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³
ãã·âãã©ãŸãŒã«ã ïŒ Arãããšãã«åºãŸãã¯ïŒåãŸãã¯ïŒåã®å¡©
çŽ ååã§çœ®æãããããšãã«åºã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé ã«èšèŒã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ã
ã·âãã©ãŸãŒã«ã ïŒ ïŒ²ãæ°ŽçŽ ååãççŽ æ°ïŒãïŒã®äœçŽã¢ã«ãã«
åºããŸãã¯ãã³ãžã«åºã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é ã«èšèŒã®ïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã ïŒ R1ãšR2ãããããççŽ æ°ïŒãïŒã®äœçŽã¢ã«
ãã«åºãè¡šãããããŸãã¯ããããçµåããçªçŽ
ååãšå ±ã«ãè¿œå ã®ç°ååãšããŠçªçŽ ååããã³
é žçŽ ååãå«æããŠãããïŒãïŒå¡è€çŽ ç°ãäžç·
ã«åœ¢æããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®ïŒâã¢
ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©ãŸãŒã«ã ïŒ R1ãšR2ããããããçµåããçªçŽ ååãšå ±
ã«ãããªãžãã«åºããããªãžã«åºããªããµãŸãªãž
ãã«åºãããã©ãžãã«åºãŸãã¯ã¢ã«ããªãã«åºã
圢æããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®ïŒâã¢ãª
ãŒã«âïŒâã¢ã«ã³ãã·âãã©ãŸãŒã«ã ïŒ æ²»ççã«æå¹ãªéã®ãäžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã·ãžã«åºã§ãããR1ãšR2ã¯åäžããŸãã¯ç°
ã€ãŠããŠããããããããæ°ŽçŽ ååãŸãã¯ã¢ã«ã
ã«åºããŸãã¯ããããçµåããçªçŽ ååããã³æŽ
ã«é žçŽ ååãå«æããããšã®ã§ããïŒãïŒå¡ç°ã
圢æããŠããããïœã¯ïŒãïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ããã³ãã®è£œè¬çã«å容ã§ããé žå¡©ããã
ã³è£œè¬çã«å容ã§ããæ äœãŸãã¯åžéå€ãå«æã
ãæäžæŽèå€ã ïŒ äžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã·ãžã«åºã§ããïŒ ã§ç€ºããããã©ãŸãã³ãå¡©åºæ§åªäœäžã§ãäžè¬åŒ
ïŒïŒ âïŒCH2ïŒoâNR1R2 ïŒïŒ ïŒåŒäžãã¯ããã²ã³ååã§ãããR1ããã³
R2ã¯åäžããŸãã¯ç°ã€ãŠããŠãããããããã
æ°ŽçŽ ååãŸãã¯ã¢ã«ãã«åºããŸãã¯ããããçµå
ããçªçŽ ååããã³æŽã«é žçŽ ååãå«æããããš
ã®ã§ããïŒãïŒå¡ç°ã圢æããŠããããïœã¯ïŒã
ïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããããã¢ã«ãã«ã¢ãã³ãšåå¿ãããããš
ãããªãäžè¬åŒïŒïŒ ïŒåŒäžãArããR1ãR2ããã³ïœã¯åèšã®æ
å³ãæã€ïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·ãã©ãŸ
ãŒã«ã®è£œæ³ã ïŒ å¡©åºæ§åªäœãææ©æº¶åªäžã®æ°ŽçŽ åç©ãã¢ã
ããçé žå¡©ãã¢ã«ã«ãªéå±ã¢ã«ã³ãã·ããŸãã¯ã¢
ãã³ã«ãã€ãŠäžããããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®
æ¹æ³ã ïŒïŒ 該æ¹æ³ãè¿œå çã«ãäžè¬åŒïŒïŒã®ãã©ãŸ
ãã³ãçªçŽ é°å²æ°äžã§ææ©æº¶åªã«æº¶ãããå¡©åºã
å ãã次ãã§äžè¬åŒïŒïŒã®ããã¢ã«ãã«ã¢ãã³
ãå ããããšãå å«ããåé ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é ãŸãã¯ç¬¬ïŒé ã®æ¹æ³ã ïŒïŒ äžè¬åŒïŒïŒ ïŒåŒäžãArã¯ããšãã«åºãŸãã¯ïŒåãŸãã¯ã
ã以äžã®å¡©çŽ ååã§çœ®æãããããšãã«åºã§ã
ããã¯æ°ŽçŽ ååãã¢ã«ãã«åºãããšãã«åºãŸã
ã¯ãã³ãžã«åºã§ããïŒ ã§ç€ºãããã¢ã«ãã«ã¢ãã€ã«ã¢ã»ããŒãããäžè¬
åŒïŒïŒ HOâïŒCH2ïŒoâNR1R2ïŒ ïŒïŒ ïŒåŒäžãR1ãšR2ã¯åäžããŸãã¯ç°ã€ãŠããŠã
ãããããããæ°ŽçŽ ååãŸãã¯ã¢ã«ãã«åºããŸã
ã¯ããããçµåããçªçŽ ååããã³æŽã«é žçŽ åå
ãå«æããããšã®ã§ããïŒãïŒå¡ç°ã圢æããŠã
ãããïœã¯ïŒãïŒã®æŽæ°ã§ããïŒ ã§ç€ºãããã¢ããã¢ã«ã³ãŒã«ãšåå¿ãããŠãåŒ
ïŒïŒ ïŒåŒäžãArããR1ãR2ããã³ïœã¯åèšã®æ
å³ãæã€ïŒã®ååç©ãåŸãåŒïŒïŒã®ååç©ãé ž
åªäœäžã®ããã©ãžã³ãçšããŠç°åããããšããæ
ãäžè¬åŒïŒïŒ ïŒåŒäžãArããR1ãR2ããã³ïœã¯åèšã®æ
å³ãæã€ïŒ ã§ç€ºãããïŒâã¢ãªãŒã«âïŒâã¢ã«ã³ãã·âãã©
ãŸãŒã«ã®è£œæ³ã ïŒïŒ åŒïŒïŒã®ã¢ã«ãã«ã¢ãã€ã«ã¢ã»ããŒããš
åŒïŒïŒã®ã¢ããã¢ã«ã³ãŒã«ãšã®åå¿ãå ±æ²žèžç
ãå¯èœã«ãã溶åªäžã§è¡ãªãããç¹èš±è«æ±ã®ç¯å²
第ïŒïŒé ã®æ¹æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8118596A FR2513996A1 (fr) | 1981-10-02 | 1981-10-02 | Derives du pyrazole, procede pour leur preparation et application en therapeutique |
| FR8118596 | 1981-10-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5867674A JPS5867674A (ja) | 1983-04-22 |
| JPH0428699B2 true JPH0428699B2 (ja) | 1992-05-15 |
Family
ID=9262693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57167759A Granted JPS5867674A (ja) | 1981-10-02 | 1982-09-28 | ãã©ãŸâã«èªå°äœãããã®è£œæ³ããã³ããã®å»è¬çšé |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4410525A (ja) |
| EP (1) | EP0076756B1 (ja) |
| JP (1) | JPS5867674A (ja) |
| DE (1) | DE3275544D1 (ja) |
| FR (1) | FR2513996A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011040266A1 (ja) | 2009-09-29 | 2011-04-07 | ç©æ°ŽååŠå·¥æ¥æ ªåŒäŒç€Ÿ | æš¹èç©å±€æ¿ |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550119A (en) * | 1983-05-23 | 1985-10-29 | Warner-Lambert Company | 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones |
| US4962120A (en) * | 1989-03-22 | 1990-10-09 | Sterling Drug Inc. | 1H-imidazole-1-acetamides |
| US5547967A (en) * | 1993-12-08 | 1996-08-20 | Kali-Chemie Pharma Gmbh | (Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and intermediates for their production and pharmaceutical compositions containing them |
| DE4341749A1 (de) * | 1993-12-08 | 1995-06-14 | Kali Chemie Pharma Gmbh | 3-(Phenylalkylaminoalkyloxy)-5-phenylpyrazol- Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1998041519A1 (en) * | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
| WO2004031203A1 (ja) | 2002-10-04 | 2004-04-15 | Kissei Pharmaceutical Co., Ltd. | ãã©ãŸãŒã«èªå°äœããããå«æããå»è¬çµæç©ããã®å»è¬çšéåã³ãã®è£œé äžéäœ |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2828529A1 (de) * | 1978-06-29 | 1980-01-17 | Kali Chemie Pharma Gmbh | Neue 5-phenylpyrazol-derivate, verfahren zu deren herstellung und arzneimittel |
| FR2479219A1 (fr) * | 1980-04-01 | 1981-10-02 | Nativelle Sa Ets | Amino-alcoxy pyrazoles, procede pour leur preparation, et medicaments les contenant |
-
1981
- 1981-10-02 FR FR8118596A patent/FR2513996A1/fr active Granted
-
1982
- 1982-09-28 JP JP57167759A patent/JPS5867674A/ja active Granted
- 1982-09-29 US US06/427,344 patent/US4410525A/en not_active Expired - Lifetime
- 1982-10-01 EP EP82401794A patent/EP0076756B1/fr not_active Expired
- 1982-10-01 DE DE8282401794T patent/DE3275544D1/de not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011040266A1 (ja) | 2009-09-29 | 2011-04-07 | ç©æ°ŽååŠå·¥æ¥æ ªåŒäŒç€Ÿ | æš¹èç©å±€æ¿ |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2513996A1 (fr) | 1983-04-08 |
| JPS5867674A (ja) | 1983-04-22 |
| EP0076756B1 (fr) | 1987-03-04 |
| FR2513996B1 (ja) | 1984-03-30 |
| EP0076756A1 (fr) | 1983-04-13 |
| US4410525A (en) | 1983-10-18 |
| DE3275544D1 (en) | 1987-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0040639B1 (en) | Isoxazole derivatives | |
| JPH054391B2 (ja) | ||
| JPS6126783B2 (ja) | ||
| JPH04257570A (ja) | ããã©ãžã³èªå°äœ | |
| KR850000216B1 (ko) | íŒíëŒì§ ì ë첎ì ì ì¡°ë°©ë² | |
| IE54473B1 (en) | Imidazolylphenyl-tetrahydropyridazines, processes for their preparation and pharmaceutical preparations containing them | |
| JPS6230780A (ja) | ïŒïŒïŒâããããªãžã³èªå°äœåã³ãããå«æããè¬å€ | |
| KR19990063850A (ko) | Nmda êžžíì ë¡ìì í ížëŒíëë¡íŽë늰 | |
| WO1992001679A1 (en) | 1,4-disubstituted piperazines | |
| JPH0428699B2 (ja) | ||
| JPH04217955A (ja) | 眮æãã³ãºã€ã³ããŒã«ã€ãã³èªå°äœåã³ãã®è£œæ³ | |
| KR920003892B1 (ko) | íŒë¡€ëŠ¬ë íí©ë¬Œ ë° ìœì íì ì©ë | |
| JPH036151B2 (ja) | ||
| JPH062744B2 (ja) | ïŒâã¢ããã«ã«ããã«ã¡ããã·âïŒâããšãã«ãã©ãŸâã«ååç©ããã®è£œæ³ãããã³ãããå«æããæäžæŽèäœçšãæããè¬å€ | |
| JPS6055069B2 (ja) | ïŒâãã§ãã«âã·ã¯ããã³ã¿ã³ã«ã«ãã³é žã®ïœâããªãžã«âã¢ããããã®è£œé æ³ãªãã³ã«ãããæå¹æåãšããæ¶çããã³é®å³å€ | |
| JPH05271208A (ja) | ïŒïŒïŒâãã³ãŸãã¢ãŒãã³èªå°äœ | |
| US4048322A (en) | Bronchially effective xanthene-9-carboxylates | |
| JP2834506B2 (ja) | æ°èŠããšãã«ãªãã·âã¢ã«ãã«ã¢ãã³èªå°äœããã®è£œæ³åã³ãã®ååç©ãå«æããå»è¬ | |
| US4801706A (en) | N-substituted-hexahydro-1,2,5-triazepines | |
| CN113429396A (zh) | äžç§äºå æè³ç¯è¡çç©åå ¶å¶å€æ¹æ³åçšé | |
| JPH0696555B2 (ja) | ã«ã«ãã¹ããªã«èªå°äœ | |
| JP2006504803A (ja) | ãã©ãŸãŒã«èªå°äœ | |
| JPS647995B2 (ja) | ||
| JPS648632B2 (ja) | ||
| JPH02286663A (ja) | ã¢ãŸãŒã«âïŒâã¢ã«ã«ã³ã¢ããããã³ãããã®è£œæ³ |